Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Mayo Clinic
Years Ended December 31, 2025 and 2024

The better the question.
The better the answer.
The better the world works.

Shape the future
with confidence

Mayo Clinic

Consolidated Financial Report, Supplementary Information, Uniform Guidance Reports and Schedule

Years Ended December 31, 2025 and 2024

Contents

Independent auditor's report 1

Consolidated financial statements

Consolidated statements of financial position 4
Consolidated statements of activities 5
Consolidated statements of cash flows 6
Notes to consolidated financial statements 7

Supplementary Information

Schedule of Expenditures of Federal Awards 42
Schedule of Expenditures of Florida State Financial Assistance 72
Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance 73

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards* 74
Report of Independent Auditors on Compliance for the Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida* 76
Schedule of Findings and Questioned Costs 80

Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

Shape the future
with confidence

Report of Independent Auditors

The Board of Trustees, Chief Executive Officer and President,
Chief Financial Officer, and Chief Administrative Officer
Mayo Clinic

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Mayo Clinic ("the Clinic"), which comprise the consolidated statements of financial position as of December 31, 2025 and 2024, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Clinic at December 31, 2025 and 2024, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Clinic and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

A member firm of Ernst & Young Global Limited

Shape the future
with confidence

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free of material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Clinic's ability to continue as a going concern for a reasonable period of time.

A member firm of Ernst & Young Global Limited

Shape the future
with confidence

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. We have not performed any procedures with respect to the audited financial statements subsequent to March 2, 2026. The Schedules of Expenditures of Federal Awards and Florida State Financial Assistance as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, respectively, are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated March 2, 2026 on our consideration of the Clinic's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Clinic's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Clinic's internal control over financial reporting and compliance.

Ernst & Young LLP

March 2, 2026, except for the Schedules of Expenditures of Federal Awards and Florida State Financial Assistance, as to which the date is June 18, 2026

A member firm of Ernst & Young Global Limited

MAYO CLINIC

Consolidated Statements of Financial Position
December 31, 2025 and 2024 (In Millions)

	2025	2024
Assets		
Current assets:		
Cash and cash equivalents	45	48
Accounts receivable for medical services	2,169	2,123
Other receivables	794	707
Other current assets	489	456
Total current assets	3,497	3,334
Investments	24,866	20,958
Other long-term assets	5,832	4,614
Property, plant, and equipment, net	7,687	7,099
Total assets	$ 41,882	$ 36,005
Liabilities and net assets		
Current liabilities:		
Accounts payable	696	778
Accrued payroll	1,120	1,004
Accrued employee benefits	188	178
Deferred revenue	85	88
Long-term variable-rate debt	620	620
Other current liabilities	587	629
Total current liabilities	3,296	3,297
Long-term debt, net of current portion	4,383	3,989
Accrued pension and postretirement benefits, net of current portion	899	827
Other long-term liabilities	2,693	2,435
Total liabilities	11,271	10,548
Net assets:		
Without donor restrictions	23,767	19,644
With donor restrictions	6,844	5,813
Total net assets	30,611	25,457
Total liabilities and net assets	$ 41,882	$ 36,005

See notes to consolidated financial statements.

MAYO CLINIC

Consolidated Statements of Activities
Years Ended December 31, 2025 and 2024 (In Millions)

	2025			2024		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Revenue, gains and other support:						
Medical service revenue	$ 18,126	$ —	$ 18,126	$ 16,554	$ —	$ 16,554
Grants and contracts	788	—	788	772	—	772
Investment return allocated to current activities	490	57	547	432	46	478
Contributions available for current activities	119	329	448	252	288	540
Other	1,617		1,617	1,451	—	1,451
Net assets released from restrictions	426	(426)	—	444	(444)	—
Total revenue, gains and other support	21,566	(40)	21,526	19,905	(110)	19,795
Expenses:						
Salaries and benefits	11,159	—	11,159	10,482	—	10,482
Supplies and services	7,485	—	7,485	6,731	—	6,731
Depreciation and amortization	772	—	772	685	—	685
Facilities	456	—	456	415	—	415
Finance and investment	186	—	186	189	—	189
Total expenses	20,058	—	20,058	18,502	—	18,502
Income (loss) from current activities	1,508	(40)	1,468	1,403	(110)	1,293
Noncurrent and other items:						
Contributions not available for current activities, net	(34)	539	505	(16)	176	160
Unallocated investment (loss) return, net	1,977	532	2,509	961	351	1,312
Income tax expense	(48)	—	(48)	(41)	—	(41)
Benefit credit	340	—	340	324	—	324
Other	(219)	—	(219)	(142)	—	(142)
Total noncurrent and other items	2,016	1,071	3,087	1,086	527	1,613
Increase in net assets before other changes in net assets	3,524	1,031	4,555	2,489	417	2,906
Pension and other postretirement benefit adjustments	599	—	599	930	—	930
Purchase of non-controlling interest	—	—	—	(15)	—	(15)
Increase in net assets	4,123	1,031	5,154	3,404	417	3,821
Net assets at beginning of year	19,644	5,813	25,457	16,240	5,396	21,636
Net assets at end of year	$ 23,767	$ 6,844	$ 30,611	$ 19,644	$ 5,813	$ 25,457

See notes to consolidated financial statements.

MAYO CLINIC

Consolidated Statements of Cash Flows
Years Ended December 31, 2025 and 2024 (In Millions)

	2025	2024
Cash flows from operating activities:		
Cash from medical services	$ 16,990	$ 15,418
Cash from external lab services	1,090	989
Cash from grants and contracts	774	785
Cash from benefactors	407	445
Cash from other activities	1,570	1,440
Cash for salaries and benefits	(10,974)	(10,236)
Cash for supplies, services, and facilities	(8,037)	(7,225)
Interest and dividends received	454	367
Interest paid	(185)	(177)
Income taxes paid	(24)	(26)
Net cash provided by operating activities	2,065	1,780
Cash flows from investing activities:		
Purchase of property, plant, and equipment	(1,338)	(1,341)
Purchases of investments	(23,678)	(21,205)
Sales and maturities from investments	22,414	20,503
Investment in unconsolidated entities	—	75
Net cash used in investing activities	(2,602)	(1,968)
Cash flows from financing activities:		
Restricted gifts, bequests, and other	244	198
Purchase of non-controlling interest	—	(15)
Proceeds from issuance of long-term debt	404	—
Payment of long-term debt	(104)	(18)
Payment on leases	(10)	(9)
Net cash provided by financing activities	534	156
Net (decrease) in cash and cash equivalents	(3)	(32)
Cash and cash equivalents at beginning of year	48	80
Cash and cash equivalents at end of year	$ 45	$ 48

See notes to consolidated financial statements.

Note 1. Organization and Summary of Significant Accounting Policies

Organization: Mayo Clinic and its Arizona, Florida, Iowa, Minnesota, Wisconsin and international affiliates (the Clinic) provide comprehensive medical care and education in clinical medicine and medical sciences and conduct extensive programs in medical research. The Clinic also provides hospital and outpatient services, and at each major location, the clinical practice is closely integrated with advanced education and research programs. The Clinic and most of its subsidiaries have been determined to qualify as tax-exempt organizations under Section 501(c)(3) of the Internal Revenue Code (the Code) and as a public charity under Section 509(a)(2) of the Code.

Basis of presentation: Included in the Clinic's consolidated financial statements are all of its wholly owned or wholly controlled subsidiaries. All significant intercompany transactions have been eliminated in consolidation. In addition, these statements follow generally accepted accounting principles applicable to the not-for-profit industry as described in the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) *Topic 958, Not-for Profit Entitie*s.

Use of estimates: The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements. Estimates also affect the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents: Cash and cash equivalents include currency on hand, demand deposits with banks or other financial institutions, and short-term investments with maturities of three months or less from the date of purchase, which are not managed by the Clinic's investment managers.

Accounts receivable for medical services: Accounts receivable for medical services are based upon the estimated amounts expected to be paid from patients and third-party payors.

Inventories: Inventories, consisting primarily of medical supplies and pharmaceuticals, are stated at the lower of cost or net realizable value.

Investments: Investments in equity and debt securities, including alternative investments, are recorded at fair value (Notes 4 and 6). Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Realized gains and losses are calculated based on the average cost method. Investment income or loss (including realized and unrealized gains and losses on investments, interest, and dividends) is included in the consolidated statements of activities.

Alternative investments (principally limited partnership interests in absolute return, hedge, private equity, real estate and natural resources funds) represent the Clinic's ownership interest in the respective partnership, which is valued at fair value based on net asset value (NAV) obtained from fund manager statements and historically audited financial statements, as a practical expedient. The investments in alternative investments may individually expose the Clinic to securities lending, short sales, and trading in futures and forward contract options and other derivative products. The Clinic's risk is limited to the investment's carrying value.

It is the Clinic's intent to maintain a long-term investment portfolio to support research, education and other activities. Accordingly, the total investment return is reported in the consolidated statements of activities in two categories. The investment return allocated to current activities is determined by a formula, which involves allocating five percent of a three-year moving average of investments related to endowments, and the matching of financing costs for the assets required for operations. Management believes this return is approximately equal to the real return that the Clinic expects to earn on its

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

investments over the long term. The unallocated investment return, included in noncurrent and other items in the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to current activities, net of investment costs.

Property, plant, and equipment: Property, plant, and equipment are carried at cost if purchased or at fair value on the date received through affiliation or donation, less accumulated depreciation. Plant and equipment are depreciated over their estimated useful lives, ranging from three to fifty years using the straight-line method. Depreciation expense includes amortization of assets recorded under capital leases.

Costs associated with the development and installation of internal-use software are accounted for in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Subtopic 350-40)* of the FASB ASC. Accordingly, internal-use software costs are expensed or capitalized and amortized according to the provisions of the accounting standard.

Leases: The Clinic determines if an arrangement is a lease at inception. Operating leases are included in other long-term assets, other current liabilities, and other long-term liabilities in the consolidated statements of financial position. Finance leases are included in property, plant, and equipment, other current liabilities, and other long-term liabilities in the consolidated statements of financial position.

Right-of-use (ROU) assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the commencement date, based on the present value of lease payments over the lease term. As most of the leases do not provide an implicit rate, the Clinic uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The implicit rate is used when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives. The lease term may include options to extend or terminate the lease when it is reasonably certain the Clinic will exercise the option.

The Clinic defines a short-term lease as any lease arrangement with a lease term of twelve months or less that does not include an option to purchase the underlying asset. Short-term lease payments are recognized as expense on a straight-line basis over the lease term and variable lease payments in the period in which the obligation is incurred.

The Clinic has lease arrangements with lease and non-lease components, which are generally accounted for separately, except the Clinic has elected the practical expedient to not separate non-lease components for real estate leases. Additionally, for certain equipment leases, the Clinic applies a portfolio approach to effectively account for the ROU assets and liabilities.

Deferred revenue: Deferred revenue consists of payments received in advance for grant, subscription, and tuition revenue. Deferred revenues are subsequently recognized as revenue in accordance with the Clinic's revenue recognition policies.

Deferred compensation: The Clinic offers eligible employees a nonqualified, tax-deferred compensation retirement plan. Employees defer compensation into the plan on a pretax basis. The compensation deferred under this plan is credited with earnings and losses as determined by the rate of return on investments selected by the plan participants. Each participant is fully vested in all deferred compensation and those earnings credited to their individual accounts. The amounts deferred under this plan is an unsecured obligation of the Clinic. The balances are reflected in investments and other long-term liabilities in the consolidated statements of financial position. The related investment return is reported in unallocated investment return, net, with a corresponding gain/loss representing benefit expense/income reported in the other - noncurrent section of the consolidated statements of activities.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

Asset retirement obligations: The Clinic accounts for the estimated cost of legal obligations associated with long-lived asset retirements in accordance with *Asset Retirement and Environmental Obligations (Topic 410)* of the FASB ASC. The asset retirement liability, recorded in other long-term liabilities, is accreted to the present value of the estimated future costs of these obligations at the end of each period.

Net assets: Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor-imposed restrictions. Accordingly, net assets and changes therein are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for an operating reserve and board-designated endowment.

Net Assets With Donor Restrictions - Net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Gifts of long-lived assets and gifts of cash restricted for the acquisition on long-lived assets are recognized as revenue when received. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Medical service revenue: Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care.

Grants and contracts: Reciprocal grants and contracts revenue is recognized when the expenses have been incurred for the purpose specified by the grantor or in accordance with the terms of the agreement. Contributed grants and contracts revenue is recorded as conditions are met or immediately if deemed an unconditional contribution. Grant and contract amounts due to the Clinic are included in other receivables.

Charity and uncompensated care: The Clinic provides health care services to patients who meet certain criteria under its Charity Care Policy without charge or at amounts less than established rates. Since the Clinic does not pursue collection of these amounts, they are not reported as revenue. The estimated cost of providing these services was $157 and $130 in 2025 and 2024, respectively, calculated by multiplying the ratio of cost to gross charges for the Clinic by the gross uncompensated charges associated with providing care to charity patients. In addition to the charges related to the direct patient care provided under the Clinic's Charity Care Policy, the Clinic has programs offered to benefit the broader community and other governmental reimbursement programs. The Clinic also participates in various state Medicaid programs for indigent patients. The estimated unreimbursed cost of providing services related to Medicaid programs totaled $627 and $622 in 2025 and 2024, respectively.

Contributions: The Clinic classifies contributions that are available for current activities as revenue, based on the lack of specific donor restriction or the presence of donor restrictions and the ability of the Clinic to meet those restrictions within the year. Contributions of a perpetual nature or not available for current activities are classified in noncurrent and other items in the consolidated statements of activities. Development expenses of $74 ($40 allocated to current and $34 allocated to noncurrent) and $67 ($51 allocated to current and $16 allocated to noncurrent) were incurred in 2025 and 2024, respectively. The current portion is recorded in expenses, and the noncurrent portion is netted against contributions not available for current activities in the consolidated statements of activities. Unconditional promises to give and contributions are reported at fair value at the time of the gift. An allowance for uncollectible pledges receivable is estimated, based on a combination of historical experience and specific identification. Conditional promises to give are recognized at fair value when the barriers to entitlement are overcome or the possibility that a condition will not be met is remote.

Note 1. Organization and Summary of Significant Accounting Policies (Continued)

The Clinic periodically receives works of art from various benefactors. These items are unique in nature and are held on display for the benefit and enjoyment of the Clinic's patients. It is the Clinic's policy to neither capitalize contributed works of art nor record the related contribution revenue.

Income from current activities: The Clinic's policy is to include in income from current activities all medical service and other revenue, grants and contracts, investment return allocated to current activities, contributions available for current activities, net assets released from restrictions, and substantially all expenses. Contributions not available for current activities, unallocated investment return, income tax expense, benefit credit, and those items not expected to recur on a regular basis are included in noncurrent and other items in the consolidated statements of activities.

Noncontrolling interest in subsidiaries: The Clinic attributed income of $2 and $5 for the years ended December 31, 2025 and 2024 , respectively, to noncontrolling interests based on the ownership percentage of the noncontrolling interests in certain of the Clinic's consolidated subsidiaries. These amounts are recognized in net assets without donor restrictions on the consolidated statements of financial position. The balance in net assets without donor restrictions was $59 and $58 for the years ended December 31, 2025 and 2024, respectively.

Subsequent events: The Clinic evaluated events and transactions occurring subsequent to December 31, 2025 through March 2, 2026, the date of issuance of the consolidated financial statements. During this period, there were no subsequent events requiring recognition in the consolidated financial statements. Additionally, there were no unrecognized events requiring disclosure.

Note 2. Liquidity and Availability

Financial assets available for general expenditure within one year of the consolidated statement of financial position date are composed of the following at December 31:

	2025	2024
Cash and cash equivalents	$ 45	$ 48
Accounts receivable	2,169	2,123
Promises to give	312	245
Grants receivable	164	160
Other receivables	318	302
Investments	15,304	12,903
Total financial assets available within one year	$ 18,312	$ 15,781

As part of a liquidity management plan, the Clinic has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the Clinic has $300 of available lines of credit for working capital (see Note 8 - Financing).

The Clinic's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. As described in Note 12 - Endowment, under the Clinic spending policy, $321 from the endowments was available as of January 1, 2026 and $311 from the endowments was available at January 1, 2025.

Note 3. Medical Service Revenue

Medical service revenue is reported at the amount that reflects the consideration to which the Clinic expects to be entitled in exchange for providing patient care. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Clinic bills the patients and third-party payors several days after the services are performed and/or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Clinic. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Clinic believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation. Generally, performance obligations satisfied over time relate to patients in the Clinic's hospital receiving inpatient acute care services. The Clinic measures the performance obligation from admission into the hospital to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge. Revenue for performance obligations satisfied at a point in time is recognized when goods or services are provided and the Clinic does not believe it is required to provide additional goods or services to the patient.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Clinic has elected to apply the optional exemption provided in *Revenue from Contracts with Customers (Topic 606-10-50-14(a))* and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The

Note 3. Medical Service Revenue (Continued)

performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Clinic determines the transaction price based on standard charges for goods and services provided to patients, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Clinic's policy, and/or implicit price concessions based on historical collection experience.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- **Medicare:** Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- **Medicaid:** Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- **Other:** Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Clinic's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Clinic. In addition, the contracts that the Clinic has with commercial payors also provide for retroactive audit and review of claims.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Clinic also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Clinic estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured, based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to medical service revenue in the period of the change. For the years ended December 31, 2025 and 2024, revenue recognized due to changes in its estimates of transaction price concessions for performance obligations satisfied in prior years were not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended December 31, 2025 and 2024 were $1 and $7, respectively.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment

Note 3. Medical Service Revenue (Continued)

agreement with the payor, correspondence from the payor, and the Clinic's historical settlement activity, including an assessment to ensure it is probable a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available) or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price for the years ended December 31, 2025 and 2024 were not significant. Receivables from third-party payors for final settlements was $68 and $57 at December 31, 2025 and 2024, respectively.

The composition of medical service revenue based on the regions of the country in which the Clinic operates, its lines of business, and timing of revenue recognition for the years ended December 31, 2025 and 2024, are as follows:

	Year Ended December 31, 2025			
	Midwest	Southeast	Southwest	Total
Hospital	$ 6,461	$ 1,614	$ 2,058	$ 10,133
Clinic	4,330	1,197	1,217	6,744
Senior Care and Nursing Home	20	—	—	20
Other	92	1	—	93
Total patient care service revenue	10,903	2,812	3,275	16,990
External lab	1,136	—	—	1,136
Total medical service revenue	$ 12,039	$ 2,812	$ 3,275	$ 18,126
Timing of revenue and recognition:				
At time services are rendered	$ 5,558	$ 1,198	$ 1,217	$ 7,973
Services transferred over time	6,481	1,614	2,058	10,153
Total	$ 12,039	$ 2,812	$ 3,275	$ 18,126

	Year Ended December 31, 2024			
	Midwest	Southeast	Southwest	Total
Hospital	$ 5,970	$ 1,407	$ 1,809	$ 9,186
Clinic	4,077	1,057	1,104	6,238
Senior Care and Nursing Home	16	—	—	16
Other	103	1	—	104
Total patient care service revenue	10,166	2,465	2,913	15,544
External lab	1,010	—	—	1,010
Total medical service revenue	$ 11,176	$ 2,465	$ 2,913	$ 16,554
Timing of revenue and recognition:				
At time services are rendered	$ 5,190	$ 1,058	$ 1,104	$ 7,352
Services transferred over time	5,986	1,407	1,809	9,202
Total	$ 11,176	$ 2,465	$ 2,913	$ 16,554

Note 3. Medical Service Revenue (Continued)

Hospital revenue includes a variety of services mainly covering inpatient procedures requiring overnight stays or outpatient operations that require anesthesia or use of complex diagnostic and surgical equipment, as well as emergency care for traumas and other critical conditions. Clinic revenue includes services mainly focused on the care of outpatients covering primary and specialty health care needs. Examples of revenue at the time services are rendered include clinical services, lab and transport, and services transferred over time include hospital and senior care revenue.

The composition of medical service revenue by payor for the years ended December 31 is as follows:

	2025	2024
Medicare	$ 4,921	$ 4,439
Medicaid	650	607
Contract	10,631	9,695
Other, including self-pay	1,924	1,813
Total	$ 18,126	$ 16,554

The Clinic's practice is to assign a patient to the primary payor and not reflect other uninsured balances (for example, coinsurance and deductibles) as self-pay. Therefore, the payors listed above contain patient responsibility components, such as coinsurance and deductibles.

The Clinic has elected the practical expedient allowed under FASB ASU 2014-09, *Revenue from Contracts with Customers (Topic 606-10-32-18)* and does not adjust the promised amount of consideration from patients and third-party payors for the effects of a significant financing component due to the Clinic's expectation that the period between the time the service is provided to a patient and the time that the patient or a third-party payor pays for that service will be one year or less. However, the Clinic does, in certain instances, enter into payment agreements with patients that allow payments in excess of one year. For those cases, the financing component is not deemed to be significant to the contract.

Note 4. Fair Value Measurements

The Clinic holds certain financial instruments that are required to be measured at fair value on a recurring basis. The valuation techniques used to measure fair value under the *Fair Value Measurement (Topic 820)* of the FASB ASC are based upon observable and unobservable inputs. The standard establishes a three-level valuation hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. The three levels are defined as follows:

Level 1: Inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the same term of the financial instrument.

Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

A financial instruments categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers or activity within Levels for the years ended December 31, 2025 and 2024.

Note 4. Fair Value Measurements (Continued)

The following tables present the financial instruments carried at fair value as of December 31,2025 and 2024, on the consolidated statements of financial position categorized by the valuation hierarchy and NAV:

	December 31, 2025				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	$ 30	$ —	$ —	$ —	$ 30
Investments:					
Cash and cash equivalents	$ 2,070	$ 404	$ —	$ —	$ 2,474
Fixed-income securities:					
U.S. government	—	2,231	—	—	2,231
U.S. government agencies	—	1,009	—	—	1,009
U.S. corporate	—	1,235	—	—	1,235
Foreign	—	19	—	—	19
Common and preferred stocks:					
U.S.	1,221	—	—	—	1,221
Foreign	926	—	—	—	926
Funds:					
Fixed income	467	—	—	—	467
Equities	1,610	981	—	—	2,591
Less securities under lending agreement	(136)	—	—	—	(136)
Investments at NAV	—	—	—	12,693	12,693
Total investments	$ 6,158	$ 5,879	$ —	$ 12,693	$ 24,730
Investments under securities lending agreement	$ 136	$ —	$ —	$ —	$ 136
Other long-term assets:					
Trust receivables	$ 74	$ 29	$ 235	$ —	$ 338
Technology-based ventures	—	—	331	—	331
Total other long-term assets	$ 74	$ 29	$ 566	$ —	$ 669
Total assets at fair value	$ 6,398	$ 5,908	$ 566	$ 12,693	$ 25,565
Liabilities:					
Securities lending payable	$ 31	$ —	$ —	$ —	$ 31
Total liabilities at fair value	$ 31	$ —	$ —	$ —	$ 31

Note 4. Fair Value Measurements (Continued)

	December 31, 2024				
	Level 1	Level 2	Level 3	NAV	Total Fair Value
Assets:					
Securities lending collateral	$ 30	$ —	$ —	$ —	$ 30
Investments:					
Cash and cash equivalents	$ 1,464	$ 161	$ —	$ —	$ 1,625
Fixed-income securities:					
U.S. government	—	2,244	—	—	2,244
U.S. government agencies	—	933	—	—	933
U.S. corporate	—	1,016	—	—	1,016
Foreign	—	26	—	—	26
Common and preferred stocks:					
U.S.	1,284	—	—	—	1,284
Foreign	711	—	—	—	711
Funds:					
Fixed income	452	—	—		452
Equities	1,346	751	—	—	2,097
Less securities under lending agreement	(76)	—	—	—	(76)
Investments at NAV	—	—	—	10,570	10,570
Total investments	$ 5,181	$ 5,131	$ —	$ 10,570	$ 20,882
Investments under securities lending agreement	$ 76	$ —	$ —	$ —	$ 76
Other long-term assets:					
Trust receivables	$ 70	$ 29	$ 247	$ —	$ 346
Technology-based ventures	—	—	295	—	295
Total other long-term assets	$ 70	$ 29	$ 542	$ —	$ 641
Total assets at fair value	$ 5,357	$ 5,160	$ 542	$ 10,570	$ 21,629
Liabilities:					
Securities lending payable	$ 30	$ —	$ —	$ —	$ 30
Total liabilities at fair value	$ 30	$ —	$ —	$ —	$ 30

The following is a description of the Clinic's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets and liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers. Level 3 primarily consists of trusts recorded at fair value based on the underlying value of the assets in the trust or discounted cash flow of the expected payment streams.

Note 4. Fair Value Measurements (Continued)

The trusts reported as Level 3 are primarily perpetual trusts managed by third parties invested in stocks, mutual funds, and fixed-income securities that are traded in active markets with observable inputs and, since the Clinic will never receive the trust assets, these perpetual trusts are reported as Level 3. In addition, technology-based ventures, composed primarily of shares in start-up companies, are recorded at fair value based on inputs relying on factors such as the financial performance of the company, sales performance, financial projections, sales projections, management representation, industry developments, market analysis, and any other pertinent factors that would affect the fair value or based on the quoted price of an otherwise identical unrestricted security of the same issuer, adjusted for the effect of the restriction.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Clinic believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2025, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	$ 5,909	$ 222	Monthly to annually	30–90 days
Private partnerships (b)	6,784	2,112		
Total alternative investments	$ 12,693	$ 2,334		

At December 31, 2024, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	$ 4,796	$ 414	Monthly to annually	30–90 days
Private partnerships (b)	5,774	1,897		
Total alternative investments	$ 10,570	$ 2,311		

(a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry “lockup” restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period, liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

Note 4. Fair Value Measurements (Continued)

(b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Clinic's ownership interest in partners' capital. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

The Clinic uses various external investment managers to diversify the investments. The largest allocation to any investment strategy manager as of December 31, 2025 and 2024 was $1,277 (7.0 percent) and $1,020 (6.6 percent) respectively.

The Clinic is required to maintain funds held by trustees under bond indentures and other arrangements. The trustee-held investments, which primarily consist of mutual funds, were $1,846 and $1,320, respectively, at December 31, 2025 and 2024, which includes segregated investments for deferred compensation plans of $1,580 and $1,317 at December 31, 2025 and 2024, respectively.

At December 31, 2025 and 2024, cash and mutual funds included segregated investments owned by Mayo Foundation for Medical Education and Research, a wholly owned subsidiary of the Clinic, for gift annuity reserves of $147 and $126, respectively.

The Clinic had internally designated investment balances of $3,717 and $3,324 at December 31, 2025 and 2024, respectively, for research, education, and capital replacement and expansion.

Note 5. Securities Lending

The Clinic has an arrangement with its investment custodian to lend Clinic securities to approved brokers in exchange for a fee. Among other provisions that limit the Clinic's risk, the securities lending agreement specifies that the custodian is responsible for lending securities and obtaining adequate collateral from the borrower. Collateral is limited to cash, government securities, and irrevocable letters of credit. Investments are loaned to various brokers and are returnable on demand. In exchange, the Clinic receives collateral. The cash collateral is shown as both an asset and a liability on the consolidated statements of financial position.

At December 31, 2025 and 2024, the aggregate market value of securities on loan under securities lending agreements totaled $136 and $76, respectively, and the total value of the collateral supporting the securities was $143 and $79, respectively, which represents 104% of the value of the securities on loan at December 31, 2025 and 2024. The cash portion of the collateral supporting the securities as of December 31, 2025 and 2024 was $31 and $30. The cash portion is presented in other current assets and other current liabilities in the consolidated statements of financial position. Noncash collateral provided to the Clinic is not recorded in the consolidated statements of financial position, as the collateral may not be sold or repledged. The Clinic's claim on such collateral is limited to the market value of loaned securities. In the event of nonperformance by the other parties to the securities lending agreements, the Clinic could be exposed to a loss.

Note 6. Property, Plant, and Equipment, Net

Property, plant, and equipment, net, at December 31 consisted of the following:

	2025	2024
Land	$ 624	$ 620
Buildings and improvements	9,463	8,629
Furniture and equipment	5,387	4,926
	15,474	14,175
Accumulated depreciation and amortization	(8,768)	(8,082)
	6,706	6,093
Construction in progress	981	1,006
Total property, plant, and equipment	$ 7,687	$ 7,099

The above costs and accumulated depreciation include costs for capitalized software, including costs capitalized in accordance with *Intangibles—Goodwill and Other, Internal-Use Software (Topic 350)* of the FASB ASC. The total cost for capitalized software was $781 and $763 at December 31, 2025 and 2024, respectively. The total accumulated amortization was $675 and $608 at December 31, 2025 and 2024, respectively. Amortization expense for capitalized software was $67 and $70 in 2025 and 2024, respectively.

Note 7. Income Taxes

Most of the income received by the Clinic and its subsidiaries is exempt from taxation under Section 501(a) of the Internal Revenue Code. Some of its subsidiaries are taxable entities, and some of the income received by otherwise exempt entities is subject to taxation as unrelated business income. The Clinic and its subsidiaries file income tax returns in the U.S., including federal and various state returns, as well as certain foreign jurisdictions. The statutes of limitations for tax years 2022 through 2024 remain open in major U.S. taxing jurisdictions in which the Clinic and subsidiaries are subject to taxation.

The Clinic's reserve for uncertain tax positions totaled $16 and $14 as of December 31, 2025 and 2024, respectively. It is not anticipated that a significant change in the reserve will occur over the next 12 months.

The Clinic’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The components of tax expense are as follows:

	Year ended December 31	
	2025	2024
Current—federal	$ 36	$ 41
Current—state	7	6
	43	47
Deferred—U.S. domestic	5	(6)
Total	$ 48	$ 41

Cash payments for income taxes were $24 and $26 for the years ended December 31, 2025 and 2024, respectively.

Note 7. Income Taxes (Continued)

The Clinic records deferred income taxes due to temporary differences between financial reporting and tax reporting for certain assets and liabilities of its taxable activities. The following is a summary of the components of deferred taxes as of December 31:

	2025	2024
Deferred compensation	$ 10	$ 10
Net operating loss	25	21
Other	4	5
Total deferred tax asset	39	36
Deferred tax liability	(1)	(1)
Valuation allowance	(35)	(27)
Net deferred tax asset	$ 3	$ 8

Note 8. Financing

Long-term debt at December 31 consisted of the following:

		2025	2024
City of Rochester, Minnesota Revenue Bonds issued in various series, subject to variable interest rates to a maximum rate of 15.00% (the average rate was 2.57% in 2025 and 3.42% in 2024), principal due in varying amounts from 2028 through 2064	Variable	$ 745	$ 545
City of Rochester, Minnesota Revenue Bonds originally issued at variable interest rate, converted in 2017 to fixed interest rate of 2.20% based on a provision to increase the rate if the federal tax rate is decreased, the rate has been adjusted to 2.67% effective January 1, 2018 through 2027, principal due in varying amounts from 2026 through 2032	Fixed	105	110
City of Rochester, Minnesota Revenue Bonds originally issued with fixed interest rate of 4.74%, converted in 2020 to fixed interest rate of 1.54% until 2030, principal due in varying amounts from 2033 through 2038	Fixed	130	130
City of Rochester, Minnesota Revenue Bonds issued in various series with fixed interest rates ranging from 2.10% to 5.00%, principal due in varying amounts from 2044 through 2055	Fixed	400	200
City of Rochester, Minnesota Health Care Facilities Revenue Refunding Bonds, series 2016B, issued with a coupon 5.00%, an effective rate of 2.97% in 2025 and 2024 after amortization of premium, principal due in varying amounts from 2029 through 2036 (unamortized premium of $33 in 2025 and $37 in 2024)	Fixed	220	220
City of Rochester, Minnesota Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.25% to 5.00%, an effective rate of 3.74% in 2025 and 2024 after amortization of premium principal due in varying amounts from 2039 through 2057 (unamortized net premium of $15 in 2025 and 2024)	Fixed	289	289
Industrial Development Authority of the City of Phoenix, Arizona issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 2.16% in 2025 and 2.97% in 2024), principal due in varying amounts from 2048 through 2052	Variable	180	180
City of Jacksonville, Florida Health Care Facilities Revenue Refunding Bonds, series 2016, issued in various series, subject to variable interest rates to a maximum rate of 10.00% (the average rate was 2.82% in 2025 and 3.51% in 2024), principal due in varying amounts from 2033 through 2047	Variable	125	125
Mayo Clinic Taxable Bonds issued with fixed interest rates ranging from 3.20% to 4.13%, principal due in varying amounts from 2039 through 2061	Fixed	1,450	1,450
Fixed-rate notes and bonds, payable to financial companies, interest rates at 1.99% to 4.71%, principal due in varying amounts from 2027 through 2062	Fixed	1,015	1,115
The Industrial Development Authority of the City of Phoenix, Arizona Health Care Facilities Revenue Bonds, series 2022, issued in various series with fixed interest rates ranging from 3.75% to 4.00%, an effective rate of 3.80% in 2025 and 2024 after amortization of premium, principal due in varying amounts from 2053 to 2057 (unamortized net premium of $3 in 2025 and 2024)	Fixed	298	298
Other notes payable		10	10
Unamortized discounts and premiums, net		56	55
Debt issuance cost		(15)	(13)
		5,008	4,714
Long-term variable-rate debt classified as current		(620)	(620)
Current maturities included in other current liabilities		(5)	(105)
Long-term debt, net of current portion		$ 4,383	$ 3,989

Note 8. Financing (Continued)

The Clinic's outstanding revenue bond issues are limited obligations of various issuing authorities payable solely by the Clinic pursuant to loan agreements between the borrowing entities and the issuing authorities. Under various financing agreements, the Clinic must meet certain operating and financial performance covenants.

At December 31, 2025, the $1,050 of variable-rate bonds consisted of variable-rate demand revenue bonds. In conjunction with the issuance of the variable-rate demand revenue bonds, the Clinic has entered into various bank standby purchase and credit agreements in the amount of $430 of which $140 will expire in January 2027, $100 will expire in April 2028, $90 will expire in January 2030 and $100 will expire in April 2030. Under the terms of these agreements, the bank will make liquidity loans to the Clinic in the amount necessary to purchase a portion of the variable-rate demand revenue bonds if not remarketed. The liquidity loans would be payable over a three- to five-year period, with the first payment due after December 31, 2026. The Clinic has provided self-liquidity for the remaining $620 of variable-rate demand revenue bonds, which have been classified as current in the accompanying consolidated statements of financial position.

The $220 fixed-rate revenue bonds Series 2016B are not callable. The remaining fixed-rate interest revenue bonds are callable from 2026 to 2058 at the option of the Clinic, at a redemption price of 100 percent of the principal amount or at a price based on U.S. Treasury rates at the time of redemption.

In April 2025, the Clinic issued fixed rate bonds in the amount of $200 par at a net premium of $6. Coupon rates range from 4.25% to 5.00% and have final maturities in varying amounts between the years 2049 to 2055. The Clinic also issued variable rate demand bonds at the same time in the amount of $200 at a daily interest rate mode with final maturities in varying amounts from the years 2062 to 2064. The fixed and variable rate debt were issued through the City of Rochester, Minnesota will be used for construction projects.

The following are scheduled maturities of long-term debt for each of the next five years, assuming the variable-rate demand revenue bonds are remarketed and the standby purchase agreements are renewed. As described above, if such bonds are not remarketed, $620 may be due in 2026 and $430 may be due in years from 2027 to 2030.

Years ending December 31:	
2026	5
2027	105
2028	45
2029	67
2030	59

Interest payments on long-term debt, net of amounts capitalized for 2025 and 2024, totaled $152 and $151, respectively. The amount of interest capitalized, net of related interest income, was $19 and $17 during 2025 and 2024. Interest expense totaled $153 and $155 for 2025 and 2024, respectively.

At December 31, 2025 and 2024, the Clinic had unsecured lines of credit available with banks that totaled $530, with varying renewable terms and interest up to 2.50 percent over various published rates. There were no amounts drawn during the years ended December 31, 2025 and 2024.

Note 9. Leases

At December 31, 2025 and 2024, the Clinic had operating and finance leases for facilities and certain equipment with lease terms ranging from 1 to 20 years, with some options to extend up to five years or terminate within one year.

Total lease expense for the years ended December 31 consisted of the following:

	2025	2024
Operating lease expense	$ 31	$ 31
Finance lease expense:		
Amortization of right-of-use assets	$ 8	$ 10
Interest on lease liabilities	1	1
Total finance lease expense	$ 9	$ 11
Short-term lease expense	$ 39	$ 29

Consolidated supplemental cash flow information related to leases as of December 31 consisted of the following:

	2025	2024
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows for operating leases	$ 72	$ 62
Operating cash flows for finance leases	$ 1	$ 1
Financing cash flows for finance leases	$ 10	$ 9
Right-of-use assets obtained in exchange for lease obligations:		
Operating leases	$ 18	$ 34
Finance leases	$ 4	$ 12

Consolidated supplemental statement of financial position information related to leases as of the years ended December 31 consisted of the following:

	2025	2024
Operating leases:		
Right-of-use assets	$ 126	$ 136
Other current liabilities	$ 28	$ 26
Other long-term liabilities	125	137
Total operating lease liabilities	$ 153	$ 163

Note 9. Leases (Continued)

	2025	2024
Finance leases:		
Property, plant, and equipment, gross	$ 59	$ 60
Accumulated depreciation	(26)	(23)
Property, plant, and equipment, net	$ 33	$ 37
Other current liabilities	$ 9	$ 8
Other long-term liabilities	23	29
Total finance lease liabilities	$ 32	$ 37
Weighted average remaining lease years:		
Operating leases	7.47	8.25
Finance leases	3.96	4.94
Weighted average discount rate:		
Operating leases	3.52 %	3.50 %
Finance leases	3.51 %	3.53 %

Maturities of lease liabilities for the next five years and thereafter consist of the following:

	Operating	Finance
2026	$ 32	$ 10
2027	29	9
2028	26	7
2029	17	5
2030	16	3
Thereafter	58	—
Minimum lease payments	178	34
Less amount representing interest	25	2
Net minimum lease payments	$ 153	$ 32

Note 10. Board-Designated Funds

Board-designated funds are subject to expenditure for the following purposes for the years ended December 31:

	2025	2024
Research	$ 1,848	$ 1,659
Education	384	344
Buildings and equipment	4	3
Charity care	15	14
Clinical	189	168
Other	1,277	1,136
Total designation for specified purpose	$ 3,717	$ 3,324

At December 31, board designated funds were classified as follows:

	2025	2024
Quasi-endowments	$ 3,468	$ 3,113
Professional liability reserve	209	178
Other	$ 40	$ 33
Total	$ 3,717	$ 3,324

Note 11. Net Assets with Donor Restrictions

The Clinic receives contributions in support of research, education, and clinical activities. Net assets with donor restrictions were available for the following purposes at December 31:

	2025	2024
Subject to expenditure for specified purposes:		
Research	$ 883	$ 749
Education	67	64
Buildings and equipment	244	199
Charity care	41	34
Clinical	89	86
Other	38	44
Total expenditure for specified purposes	1,362	1,176
Subject to passage of time:		
Pledges and trusts	1,033	730
Endowments:		
Perpetual in nature:		
Research	1,412	1,332
Education	392	374
Charity care	15	15
Clinical	229	223
Other	66	63
Pledges and trusts	283	272
Total perpetual in nature	2,397	2,279
Subject to endowment spending policy:		
Research	1,194	931
Education	498	408
Charity care	65	56
Clinical	233	185
Other	62	48
Total subject to endowment spending policy	2,052	1,628
Total endowments	4,449	3,907
Total net assets with donor restrictions	$ 6,844	$ 5,813

Note 11. Net Assets with Donor Restrictions (Continued)

Net assets were released from donor restrictions as expenditures were made, which satisfied the following restricted purposes for the years ended December 31:

	2025	2024
Research	$ 244	$ 292
Education	42	38
Buildings and equipment	88	74
Other	52	40
Total net assets released from donor restrictions	$ 426	$ 444

Note 12. Endowment

The Clinic's endowment consists of approximately 2,500 individual funds established for a variety of purposes. The endowment includes both donor-restricted endowment funds and funds designated by the Board of Trustees to function as endowments (quasi-endowments). Net assets associated with endowment funds, including quasi endowments, are classified and reported based on the existence or absence of donor-imposed restrictions. The Board of Trustees retains the right to re-designate quasi endowments for other purposes.

The Board of Trustees of the Clinic has interpreted the Minnesota State Prudent Management of Institutional Funds Act (SPMIFA) as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds, absent explicit donor stipulations to the contrary. As a result of this interpretation, the Clinic retains in perpetuity: (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the perpetual endowment, and (c) accumulations to the perpetual endowment made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund.

In accordance with SPMIFA, the Clinic considers the following factors in making a determination to appropriate or accumulate donor-restricted funds:

1. The duration and preservation of the fund
2. The purposes of the Clinic and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Clinic
7. The investment policies of the Clinic

The Clinic has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment, while seeking to maintain purchasing power of the endowment assets. Endowment assets include those assets of donor-restricted funds that the Clinic must hold in perpetuity or for a donor-specified period(s), as well as quasi-endowments. Under this policy, as approved by the Board of Trustees, the endowment assets are invested in a manner that is intended to produce a real return, net of inflation and investment management costs, of at least five percent over the long term. Actual returns in any given year may vary from this amount.

To satisfy its long-term rate-of-return objectives, the Clinic relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Clinic targets a diversified asset allocation that places a greater

Note 12. Endowment (Continued)

emphasis on equity-based and alternative investments to achieve its long-term objective within prudent risk constraints.

The Clinic has a policy of appropriating for distribution each year five percent of its endowment fund's moving average fair value over the prior 36 months as of September 30 of the preceding year in which the distribution is planned. In establishing this policy, the Clinic considered the long-term expected return on its endowment. Accordingly, over the long term, the Clinic expects the current spending policy to allow its endowment to grow at an average of the long-term rate of inflation. This is consistent with the Clinic's objective to maintain the purchasing power of the endowment assets held in perpetuity or for a specific term, as well as to provide additional real growth through new gifts and investment return.

At December 31, 2025, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	$ —	$ 4,449	$ 4,449
Quasi-endowments	3,468	—	3,468
Total funds	$ 3,468	$ 4,449	$ 7,917

Changes in endowment net assets for the year ended December 31, 2025, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	$ 3,113	$ 3,907	$ 7,020
Investment return:			
Investment income	49	58	107
Net appreciation (realized and unrealized)	450	537	987
Total investment return	499	595	1,094
Contributions	—	119	119
Appropriation of endowment assets for expenditure	(173)	(172)	(345)
Other changes:			
Transfers to create quasi-endowments	29	—	29
Endowment net assets, end of year	$ 3,468	$ 4,449	$ 7,917

Note 12. Endowment (Continued)

At December 31, 2024, the endowment net asset composition by type of fund consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Donor-restricted funds	$ —	$ 3,907	$ 3,907
Quasi-endowments	3,113	—	3,113
Total funds	$ 3,113	$ 3,907	$ 7,020

Changes in endowment net assets for the year ended December 31, 2024, consisted of the following:

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets, beginning of year	$ 2,967	$ 3,630	$ 6,597
Investment return:			
Investment income	40	46	86
Net depreciation (realized and unrealized)	249	286	535
Total investment return	289	332	621
Contributions	—	103	103
Appropriation of endowment assets for expenditure	(170)	(158)	(328)
Other changes:			
Transfers to create quasi endowments	27	—	27
Endowment net assets, end of year	$ 3,113	$ 3,907	$ 7,020

Note 13. Promises to Give

At December 31, outstanding pledges from various corporations, foundations, and individuals, included in other receivables and other long-term assets, were as follows:

	2025	2024
Pledges due:		
In less than one year	$ 312	$ 245
In one to five years	466	330
In more than five years	169	39
	947	614
Allowance for uncollectible pledges and discounts	(58)	(28)
Total	$ 889	$ 586

Note 13. Promises to Give (Continued)

Estimated cash flows from pledge receivables due after one year are discounted using a risk-adjusted rate, ranging from 1 percent to 6 percent, that is commensurate with the pledges due dates and established in the year the pledge is received.

The Clinic has received interests in various trusts, primarily split-interest, which are included in other long-term assets. The trusts are recorded at fair value, based on the underlying value of the assets in the trust or discounted cash flow using a risk-adjusted discount rate of 5.86 percent and 5.43 percent at December 31, 2025 and 2024, respectively. During the years ended December 31, 2025 and 2024, there were no contributions recorded related to the split-interest trusts. The balance of the expected payment streams was $338 and $346 at December 31, 2025 and 2024, respectively.

Note 14. Functional Expenses

The consolidated financial statements present certain expenses that are attributed to more than one program or supporting function. Therefore, expenses require allocation on a reasonable basis that is consistently applied. Benefits and payroll taxes are allocated based on factors of either salary expense or hours worked. Overhead costs that include professional services, office expenses, information technology, interest, insurance, and other similar expenses are allocated based on a variety of factors, including revenues, hours worked, and salary expense. Costs related to space, including occupancy, depreciation and amortization, and property taxes, are allocated on a square footage basis.

The expenses reported in the consolidated statements of activities for the years ended December 31, 2025 and 2024 supported the following programs and functions:

	2025							
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses
Salaries and benefits	$ 9,286	$ 233	$ 849	$ 451	$ 240	$ 27	$ 73	$ 11,159
Supplies and services	5,211	1,555	344	113	110	12	140	7,485
Depreciation and amortization	635	9	85	16	22	—	5	772
Facilities	347	5	26	17	57	1	3	456
Finance and investment	179	6	18	2	3	—	(22)	186
Total	$ 15,658	$ 1,808	$ 1,322	$ 599	$ 432	$ 40	$ 199	$ 20,058

	2024							
	Patient care	Lab and technology ventures	Research	Graduate and other education	General and administrative	Development expenses	Other activities	Total expenses
Salaries and benefits	$ 8,685	$ 213	$ 807	$ 425	$ 257	$ 33	$ 62	$ 10,482
Supplies and services	4,723	1,314	347	102	105	16	124	6,731
Depreciation and amortization	561	8	74	14	23	1	4	685
Facilities	311	6	24	15	56	1	2	415
Finance and investment	186	8	19	2	4	—	(30)	189
Total	$ 14,466	$ 1,549	$ 1,271	$ 558	$ 445	$ 51	$ 162	$ 18,502

Note 15. Employee Benefit Programs

The Clinic serves as plan sponsor for several defined benefit pension funds and other postretirement benefits.

Included in other changes in unrestricted net assets at December 31, 2025 and 2024, are the following amounts, respectively, that have not yet been recognized in net periodic cost: unrecognized actuarial losses of $906 and $317 and unrecognized prior service benefit of $98 and $109. Actuarial losses are amortized as a component of net periodic pension cost, only if the losses exceed ten percent of the greater of the projected benefit obligation or the fair value of plan assets. Unrecognized prior service benefits are amortized on a straight-line basis over the estimated life of plan participants.

Changes in plan assets and benefit obligations recognized in unrestricted net assets during 2025 and 2024 included the following:

	2025	2024
Current-year actuarial gain	$ 589	$ 936
Amortization of actuarial loss	(1)	1
Current-year prior service cost	1	—
Amortization of prior service credit	10	(7)
Pension and other postretirement benefit adjustments	$ 599	$ 930

Pension plans:

Obligations and funded status: The following is a summary of the changes in the benefit obligation and plan assets, the resulting funded status of the qualified and nonqualified pension plans, and accumulated benefit obligation as of and for the years ended December 31:

	2025	2024
Change in projected benefit obligation:		
Benefit obligation, beginning of year	$ 8,575	$ 8,889
Service cost	398	426
Interest cost	485	468
Actuarial loss (gain)	149	(796)
Benefits paid	(544)	(412)
Estimated benefit obligation at end of year	$ 9,063	$ 8,575
Change in plan assets:		
Fair value of plan assets, beginning of year	$ 11,567	$ 10,702
Actual return on plan assets	1,718	996
Employer contributions	270	281
Benefits paid	(544)	(412)
Fair value of plan assets at end of year	$ 13,011	$ 11,567

Note 15. Employee Benefit Programs (Continued)

	2025	2024
Funded status of the plans	$ 3,948	$ 2,992
Accumulated benefit obligation	$ (8,246)	$ (7,803)

Amounts recognized in the consolidated statements of financial position consist of the following at December 31:

	2025	2024
Noncurrent assets	$ 3,949	$ 2,993
Noncurrent liabilities	$ (1)	$ (1)
Net amount recognized	$ 3,948	$ 2,992

Components of net periodic benefit cost are as follows for the years ended December 31:

	2025	2024
Service cost	$ 398	$ 426
Interest cost	485	468
Expected return on plan assets	(883)	(831)
Amortization of unrecognized:		
Prior service benefit	9	(8)
Net periodic benefit cost	$ 9	$ 55

Plan assets: The largest of the pension funds is the Mayo Clinic Master Retirement Trust Plan, which holds $12,863 of the $13,011 in combined plan assets at December 31, 2025, and $11,434 of the $11,567 in combined plan assets at December 31, 2024. The investment policies described below apply to the Mayo Clinic Master Retirement Trust Plan (the Plan).

The Plan employs a global, multi-asset approach in managing its retirement plan assets. This approach is designed to maximize risk-adjusted returns over a long-term investment horizon, consistent with the nature of the pension liabilities being funded. The plan asset portfolio's target allocation for total return investment strategies, which include public equities, private equities, absolute return, and real assets, is 82.5 percent. The portfolio's target fixed-income exposure is 17.5 percent. The fixed-income exposure may include the use of long-term interest rate swap contracts structured to increase the portfolio's interest rate sensitivity and thereby provide a hedge of the plan liabilities resulting from falling long-term interest rates. Investments in private equities, real assets, and absolute return strategies are held to improve diversification and thereby enhance long-term, risk-adjusted returns. However, recognizing that these investments are not as liquid as publicly traded stocks and bonds, portfolio investment policies limit overall exposure to these assets. The portfolio's allocation to private equities and real assets is limited to a maximum of 35 percent (with a target allocation of 25 percent), and exposure to absolute return strategies is limited to a maximum of 30 percent (with a target of 25 percent). The Clinic reviews performance, asset allocation, and risk management reports for plan asset portfolios on a monthly basis.

Note 15. Employee Benefit Programs (Continued)

The fair values of the Plan's assets at December 31, 2025, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	$ 731	$ —	$ —	$ —	$ 731
Fixed income securities:					
U.S. government	—	188	—	—	188
U.S. government agencies	—	311	—	—	311
U.S. corporate	—	359	—	—	359
Foreign	—	5	—	—	5
Common and preferred stocks:					
U.S.	926	—	—	—	926
Foreign	580	—	—	—	580
Funds:					
Fixed income	134	—	—	—	134
Equities	66	876	—	—	942
Foreign	73	—	—	—	73
Investments at NAV	—	—	—	8,614	8,614
Total investments	$ 2,510	$ 1,739	$ —	$ 8,614	$ 12,863

The fair values of the Plan's assets at December 31, 2024, by asset category, are as follows:

Assets	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	NAV	Total
Cash and cash equivalents	$ 596	$ 9	$ —	$ —	$ 605
Fixed income securities:					
U.S. government	—	199	—	—	199
U.S. government agencies	—	207	—	—	207
U.S. corporate	—	350	—	—	350
Foreign	—	16	—	—	16
Common and preferred stocks:					
U.S.	1,028	—	—	—	1,028
Foreign	529	—	—	—	529
Funds:					
Fixed income	123	—	—	—	123
Equities	60	617	—	—	677
Foreign	60	—	—	—	60
Investments at NAV	—	—	—	7,640	7,640
Total investments	$ 2,396	$ 1,398	$ —	$ 7,640	$ 11,434

Note 15. Employee Benefit Programs (Continued)

The following is a description of the Plan's valuation methodologies for assets and liabilities measured at fair value. Fair value for Level 1 is based upon quoted market prices. Fair value for Level 2 is based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Inputs are obtained from various sources, including market participants, dealers, and brokers.

A financial instrument's categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Clinic's policy is to recognize transfers in and transfers out as of the actual date of the event or change in circumstances that caused the transfer. There were no significant transfers in 2025 or 2024.

The methods described above and those recorded at NAV may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following information pertains to those alternative investments recorded at NAV in accordance with *Fair Value Measurement (Topic 820)* of the FASB ASC.

At December 31, 2025, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	$ 4,511	$ 119	Monthly to annually	30–90 days
Private partnerships (b)	4,103	1,401		
	$ 8,614	$ 1,520		

At December 31, 2024, alternative investments recorded at NAV consisted of the following:

	Fair Value	Unfunded Commitment	Redemption Frequency (If Currently Eligible)	Redemption Notice Period
Absolute return/hedge funds (a)	$ 3,919	$ 142	Monthly to annually	30–90 days
Private partnerships (b)	3,721	1,323		
	$ 7,640	$ 1,465		

(a) This category includes investments in absolute return/hedge funds, which are actively managed commingled investment vehicles that derive the majority of their returns from factors other than the directional flow of the markets in which they invest. Representative strategies include high-yield credit, distressed debt, merger arbitrage, relative value, and long-short equity strategies. The fair values of the investments in this category have been estimated using the NAV per share of the investments. Investments in this category generally carry "lockup" restrictions that do not allow investors to seek redemption in the first year after acquisition. Following the initial lockup period,

Note 15. Employee Benefit Programs (Continued)

liquidity is generally available monthly, quarterly, or annually following a redemption request. Over 90 percent of the investments in this category have at least annual liquidity.

(b) This category includes limited partnership interests in closed-end funds that focus on venture capital, private equity, real estate, and resource-related strategies. The fair values of the investments in this category have been estimated using the NAV of the Plan's ownership interest in partners' capital. These investments cannot be redeemed with the funds. Distributions from each fund will be received as the underlying investments of the funds are liquidated. It is estimated that the underlying assets of most funds will generally be liquidated over a seven- to ten-year period.

No plan assets are expected to be returned to the employer during 2026.

Other postretirement benefits:

Obligations and funded status: A summary of the changes in the benefit obligation and plan assets and the resulting funded status of the other postretirement plans is as follows as of and for the years ended December 31:

	2025	2024
Change in projected benefit obligation:		
Benefit obligation at beginning of year	$ 887	$ 869
Service cost	3	4
Interest cost	49	45
Plan participants contributions	41	44
Amendments	—	—
Medicare subsidy	—	9
Actuarial loss	97	26
Benefits paid	(111)	(110)
Estimated benefit obligation at end of year	$ 966	$ 887
Change in plan assets:		
Fair value of plan assets at beginning of year	$ —	$ —
Employer contributions	70	66
Plan participants contributions	41	44
Benefits paid	(111)	(110)
Fair value of plan assets at end of year	$ —	$ —
Funded status of the plan	$ (966)	$ (887)

Amounts recognized in the consolidated statements of financial position for postretirement benefits consist of the following at December 31:

	2025	2024
Current liabilities	$ (68)	$ (61)
Noncurrent liabilities	(898)	(826)
Net amount recognized	$ (966)	$ (887)

Note 15. Employee Benefit Programs (Continued)

Components of net periodic benefit cost for other postretirement benefits are as follows for the years ended December 31:

	2025	2024
Service cost	$ 3	$ 4
Interest cost	49	45
Amortization of:		
Unrecognized prior service benefit	1	1
Unrecognized net actuarial (gain) loss	(1)	1
Net periodic benefit cost for other postretirement benefits	$ 52	$ 51

The Clinic has concluded that the prescription drug benefits under its defined benefit postretirement plan are actuarially equivalent to Medicare Part D under the Medicare Modernization Act (the Act) and that the Clinic will receive the subsidy available under the Act.

The following reflects the expected future Medicare Part D subsidy receipts:

Years ending December 31:	
2026	$ 5
2027	5
2028	5
2029	5
2030	5
2031–2035	23

Plan trend rates are the annual rates of increase expected for the benefits payable from the plan; these rates include health care cost trends plus the leveraging effect of plan design. The assumed plan trend rate is 5.50 percent.

Pension and postretirement benefits:

Assumptions: Weighted average assumptions used to determine pension and postretirement benefit obligations at the measurement date are as follows:

	Pension Benefits		Postretirement Benefits	
	2025	2024	2025	2024
Discount rate	5.83%	5.86%	5.57%	5.74%
Rate of compensation increase	3.69%	3.69%	N/A	N/A

Note 15. Employee Benefit Programs (Continued)

Weighted-average assumptions used to determine net periodic pension and postretirement benefit cost are as follows:

	Pension Benefits		Postretirement Benefits	
	2025	2024	2025	2024
Discount rate	5.86%	5.43%	5.74%	5.42%
Expected long-term return on plan assets	7.50%	7.50%	N/A	N/A
Rate of compensation increase	3.69%	3.67%	N/A	N/A

The Clinic utilizes a building block approach in determining the expected long-term rate of return for its plan assets. First, historical data on individual asset class returns are studied. Next, the historical correlation among and between asset class returns is studied under both normal conditions and in times of market turbulence. Then, various mixes of asset classes are considered under multiple long-term investment scenarios. Finally, after considering liquidity concerns related to the use of certain alternative asset classes, the plan sponsor selects the portfolio blend that it believes will produce the highest expected long-term return on a risk-adjusted basis.

Cash flows:

Contributions: The Clinic expects to contribute $238 to its pension plans in 2026.

Estimated future benefit payments: The following benefit payments, which reflect expected future service, as appropriate, are expected to be paid:

	Pension Benefits	Postretirement Benefits
Years ending December 31:		
2026	$ 642	$ 70
2027	647	73
2028	652	75
2029	661	76
2030	659	77
2031-2035	3,413	380

In addition to the defined benefit plans, the Clinic sponsors various defined contribution benefit plans. Expense recognized by the Clinic for those plans was $165 and $151 for 2025 and 2024, respectively.

Note 16. General and Professional Liability Insurance

The Clinic insures substantially all general and professional liability risks through a combination of a wholly owned captive insurance company and self-insurance. The insurance program combines various levels of self-insured retention with excess commercial insurance coverage. Actuarial consultants have been retained to assist in the estimation of outstanding general and professional liability losses.

Note 16. General and Professional Liability Insurance (Continued)

The Clinic's general and professional liability as reported in the accompanying consolidated statements of financial position was $207 and $177 at December 31, 2025 and 2024, respectively. Provisions for the general and professional liability risks are based on an actuarial estimate of losses using the Clinic's actual loss data, adjusted for industry trends and current conditions, and considering an evaluation of claims by the Clinic's legal counsel. The provision includes estimates of ultimate costs for both reported claims and claims incurred but not reported.

Activity in the liability is summarized as follows for the years ended December 31:

	2025	2024
Balance, beginning of year	$ 177	$ 164
Incurred related to captive insurance company liability:		
Current year	43	40
Prior years	29	15
Total incurred	72	55
Paid related to captive insurance company liability:		
Current year	—	—
Prior years	(40)	(60)
Total paid	(40)	(60)
Net change in self-insurance liability	(2)	18
Balance, end of year	$ 207	$ 177

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities

At December 31, other receivables consisted of the following:

	2025	2024
Pledges receivable	$ 312	$ 245
Grants receivable	164	160
Rebates receivable	106	85
Pharmacy receivable	68	60
Interest receivable	48	40
Royalty receivable	14	12
Other tax receivable	—	6
Other	82	99
Total other receivables	$ 794	$ 707

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other current assets consisted of the following:

	2025	2024
Inventories	$ 279	$ 253
Prepaid expenses	179	173
Other	31	30
Total other current assets	$ 489	$ 456

At December 31, other long-term assets consisted of the following:

	2025	2024
Pension asset	$ 3,949	$ 2,993
Pledges receivable	578	341
Trust receivables	338	346
Technology-based ventures	331	295
Oil and gas interests	239	254
Operating lease right-of-use asset	126	136
Notes receivable	97	78
Prepaid maintenance	92	76
Long-term portion of deferred tax asset	2	8
Investments in unconsolidated entities	—	2
Other	80	85
Total other long-term assets	$ 5,832	$ 4,614

Note 17. Other Receivables, Other Current and Long-Term Assets, and Other Current and Long-Term Liabilities (Continued)

At December 31, other current liabilities consisted of the following:

	2025	2024
Other taxes	$ 112	$ 103
Current portion of professional and general liability	61	58
Current portion of long-term disability	53	56
Refunds/recoupments	53	30
Short-term disability	39	33
Real estate tax accrual	29	27
Operating lease liability	28	26
Accrued interest	20	21
Oil and gas liability	18	36
Medicare settlements liability	17	21
Current portion of workers' compensation liability	13	13
Finance lease liability	9	8
Current maturities of long-term debt	5	105
Other	130	92
Total other current liabilities	$ 587	$ 629

At December 31, other long-term liabilities consisted of the following:

	2025	2024
Deferred compensation	$ 1,580	$ 1,317
Long-term disability	266	270
Professional and general liability	146	119
Operating lease liability	124	138
Retirement community obligations	86	88
Electronic medical record	81	90
Gift annuities	77	72
Financing obligations	58	59
Asset retirement obligation	56	55
Trust obligations	47	49
Workers’ compensation liability	36	35
Contract deposit	25	25
Finance lease liability	23	29
Deferred gain	16	18
Other	72	71
Total other long-term liabilities	$ 2,693	$ 2,435

Note 18. Other Revenue

For the years ended December 31, other revenue consisted of the following:

	2025	2024
Retail pharmacy sales	$ 819	$ 660
Royalties	140	191
Retail stores	87	86
Oil and gas producing activities	75	83
Graduate medical and other education revenue	60	61
Technology commercialization, health information, and medical products	59	46
Cafeteria revenue	46	41
Other	331	283
Total other revenue	$ 1,617	$ 1,451

The Clinic's retail pharmacy recognizes revenue at the time the customer takes possession of the pharmaceuticals. Each prescription claim is its own arrangement with the customer and is a separate and distinct performance obligation. The nature, amount, timing, and uncertainty of revenue from pharmacy claims are not significantly impacted by economic factors.

Note 19. Commitments and Contingencies

The Clinic has various construction projects in progress related to patient care, research, and educational facilities. The estimated costs committed to complete the various projects at December 31, 2025 and 2024, is $6,955 and $5,756 respectively, all of which is expected to be expended over the next three to five years. This includes a $5 billion initiative for the Rochester, Minnesota campus project with five new buildings and related technology and infrastructure investments. It also includes a $2 billion initiative for the Phoenix, Arizona campus project with more than one million square feet of new clinical space across three buildings designed around integrated care neighborhoods, along with technology and infrastructure investments.

While the Clinic is self-insured for a substantial portion of its general and workers' compensation liabilities, the Clinic maintains commercial insurance coverage against catastrophic loss. Additionally, the Clinic maintains a self-insurance program for its long-term disability coverage. The provision for estimated self-insured claims includes estimates of the ultimate costs for both reported claims and claims incurred but not reported.

The Clinic is a defendant in various lawsuits arising in the ordinary course of business and records an estimated liability for probable claims. Although the outcome of these lawsuits cannot be predicted with certainty, management believes the ultimate disposition of such matters will not have a material effect on the Clinic's consolidated financial position or consolidated statement of activities.

Supplementary Information

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF AGRICULTURE									
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	S005163	Pennsylvania State University	S005163		$ 2,542	$ 2,542	RESEARCH AND DEVELOPMENT	472,270,751
TOTAL DEPARTMENT OF AGRICULTURE						**$ 2,542**			
DEPARTMENT OF DEFENSE									
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	HR0011-24-C-0332				$ 1,286,232	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-16-1-3173				$ 2,013	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2007			$ 256,540	$ 1,092,283	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2017				$ 370,915	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-19-C-2019				$ 194,131	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
BASIC AND APPLIED SCIENTIFIC RESEARCH	12.300	N00014-22-C-2019				$ 741,968	$ 3,687,542	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0100				$ 91,404	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0110			$ 210,000	$ 554,583	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0234				$ 692,597	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0298				$ 137,851	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0327	U.T. Southwestern Medical Center	HT9425-23-1-0327		$ 35,453	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0328			$ 24,663	$ 169,971	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0448	University of Minnesota	HT9425-23-1-0448		$ 45,088	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0485	Boston Scientific Corporation	HT9425-23-1-0485		$ 219,121	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0488				$ 1,950,470	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0681	Targepeutics, Inc.	HT9425-23-1-0681		$ 187,000	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0752				$ 146,863	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0754				$ 117,834	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0900	University of Alabama at Birmingham	HT9425-23-1-0900		$ 165,728	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0980	University of Pennsylvania	HT9425-23-1-0980		$ 42,602	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-0988	TILT Biotherapeutics Oy	HT9425-23-1-0988		$ 142,964	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-1-1079			$ 57,521	$ 441,472	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-2-0026				$ 485,946	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-3-0001	Metis Foundation	HT9425-23-3-0001		$ 10,703	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-23-C0067	Zymeron Corporation	HT9425-23-C0067		$ 183,422	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0065				$ 139,242	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0113	BioVie, Inc.	HT9425-24-1-0113		$ 6,055	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0154				$ 179,587	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0155				$ 235,044	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0208				$ 218,229	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0232				$ 429,805	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0298				$ 223,840	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0306	Columbia University Medical Center	HT9425-24-1-0306		$ 297,809	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0357				$ 240,864	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0609				$ 438,053	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0619				$ 214,948	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0622				$ 23,605	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0639	University of Minnesota	HT9425-24-1-0639		$ 79,395	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0669				$ 308,353	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0826				$ 235,223	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0906				$ 137,644	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-0928				$ 171,586	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1100				$ 502,995	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1101			$ 158,799	$ 1,887,055	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1102	Georgia College & State University	HT9425-24-1-1102		$ 41,167	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1104				$ 84,937	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-24-1-1105				$ 188,673	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0007				$ 388,852	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0155				$ 91,597	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0206			$ 3,399	$ 167,862	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0287				$ 384,941	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0288				$ 82,061	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0289	Dartmouth-Hitchcock Medical Center	HT9425-25-1-0289		$ 2,976	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0309				$ 157,114	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0458				$ 93,751	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0631				$ 67,130	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0726				$ 16,269	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0729				$ 43,833	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0731				$ 74,267	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0836				$ 8,326	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0845				$ 18,883	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0974				$ 63,173	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HT9425-25-1-0982	University of Massachusetts Chan Medical School	HT9425-25-1-0982		$ 901	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	HU00012520013	Henry M. Jackson Foundation	HU00012520013		$ 485,364	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0115				$ 69,459	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0292				$ 274,692	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-1-0293				$ 118,798	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0265				$ 227,230	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0266				$ 338,894	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0268				$ 62,751	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0269				$ 88,726	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-1-0644	Massachusetts Eye & Ear	W81XWH-17-1-0644		$ 949	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0037	University of Alabama at Birmingham	W81XWH-17-2-0037		$ -	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-17-2-0073	University of Pittsburgh	W81XWH-17-2-0073		$ 4,983	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0563				$ 211,558	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0564			$ 74,450	$ 653,420	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0577	University of Minnesota	W81XWH-18-1-0577		$ 15,566	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0650				$ 5,762	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0491	MD Anderson Cancer Center	W81XWH-19-1-0491		$ 2,596	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534			$ 792,560	$ 1,583,884	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0534				$ 28,103	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0780	Dana-Farber Cancer Institute	W81XWH-19-1-0780		$ 5,488	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0066	ARMR Systems Inc	W81XWH-19-2-0066		$ 19,878	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0514			$ 9,964	$ 91,051	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0524	Prytime Medical Devices, Inc.	W81XWH-20-1-0524		$ 148,463	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0662				$ 132,909	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0752				$ 213	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-2-0055	University of Pittsburgh	W81XWH-20-2-0055		$ 5,558	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0063				$ 325,864	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0121	Prytime Medical Devices, Inc.	W81XWH-21-1-0121		$ 243,157	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0160	Emory University	W81XWH-21-1-0160		$ 695	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0405				$ 305,764	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0475				$ 127,176	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0489				$ 199,605	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0490			$ 18,613	$ 193,328	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0665	University of Alabama at Birmingham	W81XWH-21-1-0665		$ 14,539	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0678				$ 217,415	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0704				$ 350,018	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0705				$ 31,669	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0706				$ 54,454	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0796	University of Alabama at Birmingham	W81XWH-21-1-0796		$ 3,593	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0798				$ 318	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0827	Cure HHT Foundation	W81XWH-21-1-0827		$ 13,356	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0867				$ 185,416	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-1-0888				$ 176,779	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-2-0036			$ 40,999	$ 296,865	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-21-9-0014	University of Pittsburgh	W81XWH-21-9-0014		$ 61,155	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0201	University of Iowa	W81XWH-22-1-0201		$ 178,310	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0245				$ 992,682	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0288				$ 387,766	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0289			$ 47,081	$ 220,495	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0634				$ 15,464	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0670				$ 13,772	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0860				$ 502,567	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0969				$ 223,281	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0970	Beckman Research Institute of the City of Hope	W81XWH-22-1-0970		$ 51,000	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-1-0999	Mount Sinai Medical Center	W81XWH-22-1-0999		$ 10,826	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-2-0020	Sloan-Kettering Institute for Cancer Research	W81XWH-22-2-0020		$ 76,072	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-3-0001	University of Alabama at Birmingham	W81XWH-22-3-0001		$ 24,273	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-22-KCRP-TRPA	H. Lee Moffit Cancer Center & Research Institute	W81XWH-22-KCRP-TRPA		$ 10,907	$ 23,851,993	RESEARCH AND DEVELOPMENT	472,270,751
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	11207-N24-A16	The Geneva Foundation	11207-N24-A16		$ 8,680	$ 236,133	RESEARCH AND DEVELOPMENT	472,270,751
UNIFORMED SERVICES UNIVERSITY MEDICAL RESEARCH PROJECTS	12.750	HU00012420124	Henry M. Jackson Foundation	HU00012420124		$ 227,453	$ 236,133	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	140D0422C0053	Luna Innovations , Inc.	140D0422C0053		$ 206,365	$ 206,365	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	6973GH-23-T-00009				$ 16,698	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	75N93019C00052	University of Georgia	75N93019C00052		$ 426,415	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CONTRACT	12.RD	75N93019C00056	Crestone, Inc.	75N93019C00056		$ 429	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	DE-AC05-76RL01830	Battelle Memorial Institute	DE-AC05-76RL01830		$ 4,814	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	FA864924P0552	Perfusion Medical, Inc.	FA864924P0552		$ 354,792	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	FA8650-19-C-6979				$ 21,202	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-13-D-0123				$ 1	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-18-D-0024				$ 9,617	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-22-C-0095				$ 1,562,545	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-24-C-0064			$ 15,000	$ 415,295	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-25-D-0002				$ 609,478	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-25-D-0003				$ 565,653	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	H98230-25-D-0004/0001				$ 2,609,734	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	HT9425-24C-0010	InnoVital Systems, Inc.	HT9425-24C-0010		$ 77,327	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	MTEC-23-04-AFIRM	Wake Forest University Health Scienc	MTEC-23-04-AFIRM	$ 21,669	$ 418,032	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	MTEC-25-06-ExModernize-011				$ 144,807	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	N6833524C0396	Rush River Research Corp.	N6833524C0396		$ 34,227	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	NNJ15HK11B	KBR Wyle Services, LLC	NNJ15HK11B		$ 185,309	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	W81XWH-15-9-001	University of Pittsburgh	W81XWH-15-9-001		$ 50,558	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	W81XWH-20-1-0930	University of New Mexico	W81XWH-20-1-0930		$ 5,913	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	W81XWH-20-C-0013	Engineering & Computer Simulation	W81XWH-20-C-0013		$ 12,380	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	12.RD	WAR53	University of Florida	WAR53		$ 49	$ 7,525,275	RESEARCH AND DEVELOPMENT	472,270,751
TOTAL DEPARTMENT OF DEFENSE					**$ 1,731,258**	**$ 35,507,308**			
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT									
SUPPORTIVE HOUSING FOR THE ELDERLY	14.157	Supportive Housing For The Elderly				$ 87,921	$ 87,921	N/A	-
SECTION 8 HOUSING CHOICE VOUCHERS	14.871	Section 8 Housing Choice Vouchers				$ 53,224	$ 53,224	HOUSING VOUCHER CLUSTER	53,224
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT						**$ 141,145**			
DEPARTMENT OF JUSTICE									
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION, AND DEVELOPMENT PROJECT GRANTS	16.560	15PNIJ-24-GG-03844-MUMU				$ 205,221	$ 205,221	RESEARCH AND DEVELOPMENT	472,270,751
CRIME VICTIM ASSISTANCE	16.575	Crime Victim Assistance				$ 34,254	$ 34,254	N/A	-
TOTAL DEPARTMENT OF JUSTICE						**$ 239,475**			
DEPARTMENT OF THE TREASURY									
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	University of Wisconsin-Madison	435100-G23		$ 383,457	$ 503,659	N/A	-
COVID-19 CORONAVIRUS STATE AND LOCAL FISCAL RECOVERY FUNDS	21.027	COVID-19	Arizona State Board of Nursing	ARS 36-1803		$ 120,202	$ 503,659	N/A	-
TOTAL DEPARTMENT OF THE TREASURY						**$ 503,659**			
NATIONAL AERONAUTICS & SPACE ADMINISTRATION									
SCIENCE	43.001	80NSSC21K0299				$ 173,756	$ 173,756	RESEARCH AND DEVELOPMENT	472,270,751
EXPLORATION	43.300	80NSSC20K1139				$ 6,645	$ 6,645	RESEARCH AND DEVELOPMENT	472,270,751
TOTAL NATIONAL AERONAUTICS & SPACE ADMINISTRATION						**$ 180,401**			
NATIONAL SCIENCE FOUNDATION									
ENGINEERING	47.041	NSF #2122901	National Science Foundation	NSF #2122901		$ 63,665	$ 247,053	RESEARCH AND DEVELOPMENT	472,270,751
ENGINEERING	47.041	NSF #2152869	Texas A&M University	NSF #2152869		$ 66,694	$ 247,053	RESEARCH AND DEVELOPMENT	472,270,751
ENGINEERING	47.041	NSF #2229279	Arizona State University	NSF #2229279		$ 17,496	$ 247,053	RESEARCH AND DEVELOPMENT	472,270,751
ENGINEERING	47.041	NSF2111884	Sequitur Health Corporation	NSF2111884		$ 99,198	$ 247,053	RESEARCH AND DEVELOPMENT	472,270,751
MATHEMATICAL AND PHYSICAL SCIENCES	47.049	NSF #10				$ 32	$ 32	RESEARCH AND DEVELOPMENT	472,270,751
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF #2419319				$ 205,390	$ 743,526	RESEARCH AND DEVELOPMENT	472,270,751
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF #2521755				$ 122,717	$ 743,526	RESEARCH AND DEVELOPMENT	472,270,751
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2041339			$ 94,045	$ 231,131	$ 743,526	RESEARCH AND DEVELOPMENT	472,270,751
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2123900				$ 124,323	$ 743,526	RESEARCH AND DEVELOPMENT	472,270,751
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING	47.070	NSF 2200058	Oxalo Therapeutics, Inc.	NSF 2200058		$ 59,965	$ 743,526	RESEARCH AND DEVELOPMENT	472,270,751
BIOLOGICAL SCIENCES	47.074	NSF #2553152				$ 116,795	$ 179,239	RESEARCH AND DEVELOPMENT	472,270,751
BIOLOGICAL SCIENCES	47.074	NSF 23494	Iowa State University	NSF 23494		$ 62,444	$ 179,239	RESEARCH AND DEVELOPMENT	472,270,751
INTEGRATIVE ACTIVITIES	47.083	NSF #2408753				$ 316,105	$ 316,105	RESEARCH AND DEVELOPMENT	472,270,751
NSF TECHNOLOGY, INNOVATION, AND PARTNERSHIPS	47.084	NSF #2328351	Montana State University	NSF #2328351		$ 32,762	$ 32,762	RESEARCH AND DEVELOPMENT	472,270,751
TOTAL NATIONAL SCIENCE FOUNDATION					**$ 94,045**	**$ 1,518,717**			

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DEPARTMENT OF VETERAN AFFAIRS									
CONTRACT	64.RD	36C26223C0234				$ 71,433	$ 266,036	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	64.RD	IPA AGREEMENT				$ 194,603	$ 266,036	RESEARCH AND DEVELOPMENT	472,270,751
TOTAL DEPARTMENT OF VETERAN AFFAIRS						**$ 266,036**			
DEPARTMENT OF EDUCATION									
FEDERAL PELL GRANT PROGRAM	84.063	PELL #1				$ 77,612	$ 77,612	STUDENT FINANCIAL ASSISTANCE	16,682,864
FEDERAL DIRECT STUDENT LOANS	84.268	Federal Direct Student Loans				$ 16,605,252	$ 16,605,252	STUDENT FINANCIAL ASSISTANCE	16,682,864
TOTAL DEPARTMENT OF EDUCATION						**$ 16,682,864**			
DEPARTMENT OF HEALTH AND HUMAN SERVICES									
CHRONIC DISEASES: RESEARCH, CONTROL, AND PREVENTION	93.068	DP06703				$ 1,005,371	$ 1,005,371	RESEARCH AND DEVELOPMENT	472,270,751
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	93.073	DD00053	University of Florida	DD00053		$ 21,501	$ 21,501	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	NU27DD000020	Great Lakes Hemo Foundation	NU27DD000020		$ 11,374	$ 11,374	RESEARCH AND DEVELOPMENT	472,270,751
PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES	93.083	NH23IP922656	American Society Clinical Oncology	NH23IP922656		$ 43,226	$ 43,226	RESEARCH AND DEVELOPMENT	472,270,751
PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES	93.084	NU50CK000628	Minnesota Department of Health	NU50CK000628		$ 102,888	$ 102,888	RESEARCH AND DEVELOPMENT	472,270,751
FOOD AND DRUG ADMINISTRATION RESEARCH	93.103	75F40119D10037	Harvard Pilgrim Health Care	75F40119D10037		$ 94,489	$ 94,489	RESEARCH AND DEVELOPMENT	472,270,751
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	HRSA-22-145	Cure HHT Foundation	HRSA-22-145		$ 87,730	$ 106,424	RESEARCH AND DEVELOPMENT	472,270,751
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24052	Great Lakes Hemo Foundation	MC24052		$ 18,694	$ 106,424	RESEARCH AND DEVELOPMENT	472,270,751
ENVIRONMENTAL HEALTH	93.113	ES33892	University of Georgia	ES33892		$ 6,481	$ 163,159	RESEARCH AND DEVELOPMENT	472,270,751
ENVIRONMENTAL HEALTH	93.113	ES36131	Indiana University School of Medicine	ES36131		$ 156,678	$ 163,159	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29322			$ 94,810	$ 585,413	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29754	University of North Carolina at Chapel Hill	DE29754		$ 3,022	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE29832			$ 231,074	$ 772,800	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE30596	Mount Sinai School of Medicine	DE30596		$ 71,986	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE31296	University of Michigan	DE31296		$ 1,155	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE31439	Pennsylvania State University	DE31439		$ 199,123	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE32344	Baylor College of Medicine	DE32344		$ 7,031	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE34500				$ 11,663	$ 1,652,193	RESEARCH AND DEVELOPMENT	472,270,751
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC28844	The Research Institute at Nationwide Children's Hospital	MC28844		$ 11,169	$ 11,169	RESEARCH AND DEVELOPMENT	472,270,751
GRANTS TO INCREASE ORGAN DONATION	93.134	HS33878	University of Kansas Medical Center	HS33878		$ 209	$ 142,582	RESEARCH AND DEVELOPMENT	472,270,751
GRANTS TO INCREASE ORGAN DONATION	93.134	HS55158			$ 94,443	$ 142,373	$ 142,582	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG06379			$ 51,670	$ 406,853	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG06834	The Broad Institute, Inc.	HG06834		$ 47,781	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG09650	University of North Carolina at Chapel Hill	HG09650		$ 7,655	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG09668	Case Western Reserve University	HG09668		$ 4,273	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG10166	Cincinnati Children's Hospital	HG10166		$ 35,484	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG11461			$ 512,823	$ 652,334	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG11710				$ 223,284	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG11899				$ 579,465	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG12402	University of North Carolina at Chapel Hill	HG12402		$ 58,663	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG12748	University of Texas Health at Houston	HG12748		$ 177,064	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG13341				$ 58,561	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG13425			$ 18,499	$ 468,119	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
HUMAN GENOME RESEARCH	93.172	HG13718			$ 228,323	$ 313,964	$ 3,033,500	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC019564				$ 27,784	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC021115			$ 3,503	$ 24,847	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC12519				$ 619,906	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC14942				$ 675,413	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC18920	Ohio State University	DC18920		$ 17,926	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19114			$ 12,719	$ 669,230	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC19402	Michigan State University	DC19402		$ 78,977	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC20175	Oregon Health & Science University	DC20175		$ 2,790	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC22228				$ 125,472	$ 2,242,345	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12185				$ 479,488	$ 628,816	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12307	University of Minnesota	AT12307		$ 93,140	$ 628,816	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT12871	University Illinois-Urbana Champaign	AT12871		$ 56,188	$ 628,816	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS028475				$ 70	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS26379	University of Minnesota	HS26379		$ 260	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28583	University of Minnesota	HS28583		$ 10,997	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS28639			$ 13,246	$ 244,867	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29460	University of Minnesota	HS29460		$ 47,930	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29744	University of Minnesota	HS29744		$ 19,918	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS29744				$ 919,238	$ 1,243,280	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160368	REMastered Sleep LLC	HL160368		$ 20,771	$ 847,682	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL160619				$ 741,106	$ 847,682	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL162131	Minnesota HealthSolutions Corp	HL162131		$ 2,711	$ 847,682	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL168173	Arizona State University	HL168173		$ 53,356	$ 847,682	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233	HL176010				$ 29,738	$ 847,682	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH118453	Yale University	MH118453		$ 76,993	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121191	Harvard School - Public Health	MH121191		$ 86,129	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH121924				$ 601,684	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH122258				$ 259,553	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124655			$ 119,063	$ 377,536	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH125935	University of Washington	MH125935		$ 3,776	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH128296				$ 142,268	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129278	Advanced MRI Technologies, LLC	MH129278		$ 17,775	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH129301	Yale University	MH129301		$ 134,619	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131254				$ 55,346	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH131623			$ 979,145	$ 1,186,559	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH132746	Arizona State University	MH132746		$ 34,392	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH136069	Yale University	MH136069		$ 478,997	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
MENTAL HEALTH RESEARCH GRANTS	93.242	MH137213				$ 287,783	$ 3,743,410	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA20735	University of Nebraska Medical Center	AA20735		$ 404,826	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA21171				$ 379,651	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA26974				$ 406,648	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA27486				$ 883,073	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA28050				$ 4,101	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA28258	Emory University	AA28258		$ 90,850	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA29258				$ 350,779	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA30184				$ 65,284	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA30273				$ 396,250	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA31167				$ 58,006	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA31257			$ 19,268	$ 676,704	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA31965				$ 57,156	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA32254	Emory University	AA32254		$ 13,752	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
ALCOHOL RESEARCH PROGRAMS	93.273	AA32553				$ 10,261	$ 3,797,341	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	CA278594			$ 10,477	$ 1,729,527	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA40316	Hennepin Healthcare Research Institute	DA40316		$ 21,163	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA42492				$ 288,554	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA47003	Yale University	DA47003		$ 8,891	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55017			$ 58,775	$ 591,635	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55167				$ 242,845	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA55848				$ 115,295	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA56469			$ 200,020	$ 412,103	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	DA57928				$ 303,252	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	NS1133515			$ 342,883	$ 602,957	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DRUG USE AND ADDICTION RESEARCH PROGRAMS	93.279	NS113844	NYU Grossman School of Medicine	NS113844		$ 12,359	$ 4,328,581	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB001981				$ 392,468	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17095				$ 543,724	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB17197				$ 409,386	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB19403			$ 2,909	$ 5,248	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB27049	Northwestern University	EB27049		$ 99,388	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28590				$ 94,705	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB28936				$ 124,682	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB293388			$ 39,659	$ 386,782	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB30529			$ 61,875	$ 447,651	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31040	Duke University	EB31040		$ 46,964	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31790				$ 615,740	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB31992	Massachusetts Institute of Technology	EB31992		$ 85,238	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB32958	University of Southern California	EB32958		$ 723	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33008				$ 787,529	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33356	Pennsylvania State University	EB33356		$ 2,415	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB33725	Health Discovery Labs	EB33725		$ 62,741	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB34346				$ 260,604	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35403	Arizona State University	EB35403		$ 55,328	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB35553			$ 57,597	$ 317,045	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB36541				$ 97,919	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB36987				$ 202,745	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB37399				$ 38,386	$ 5,077,411	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD12388	Northern Arizona University	MD12388		$ 14,173	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD16230				$ 137,587	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17217				$ 190,795	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17342	University of Minnesota	MD17342		$ 1,909,963	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD17690	Moorhouse School of Medicine	MD17690		$ 9,370	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19360				$ 71,813	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19549	Minnesota HealthSolutions Corp	MD19549		$ 23,866	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19644				$ 146,846	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD19990	University of Minnesota	MD19990		$ 39,952	$ 2,544,365	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	AG75941	University of Connecticut	AG75941		$ 124,679	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	AG79754	University of Minnesota	AG79754		$ 347,407	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	AG79758	Sanford-Burnham Medical	AG79758		$ 111,198	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	AG79779	Johns Hopkins University	AG79779		$ 420,700	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	AI142773				$ 3,271	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	CA268091	University of Michigan	CA268091		$ 13,023	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	CA268103				$ 548,996	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	CA268108	University of Pittsburgh	CA268108		$ 18,695	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	CA275669				$ 998,089	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	DK112326				$ 383,477	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD023121				$ 10,913,538	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD32581	Harvard Medical School	OD32581		$ 8,607	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD32701	Massachusetts General Hospital	OD32701		$ 130,733	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD37955				$ 28,539	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD37955				$ 6,608	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
TRANS-NIH RESEARCH SUPPORT	93.310	OD38065	Emory University	OD38065		$ 42,831	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD38392				$ 57,721	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
TRANS-NIH RESEARCH SUPPORT	93.310	OD39975				$ 37,072	$ 14,195,184	RESEARCH AND DEVELOPMENT	472,270,751
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING ANE STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	HCK000001	Johns Hopkins University	HCK000001		$ 47,106	$ 78,066	RESEARCH AND DEVELOPMENT	472,270,751
PROTECTING AND IMPROVING HEALTH GLOBALLY: BUILDING ANE STRENGTHENING PUBLIC HEALTH IMPACT, SYSTEMS, CAPACITY AND SECURITY	93.318	NU3HCK000006	Vanderbilt University Medical Center	NU3HCK000006		$ 30,960	$ 78,066	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002377			$ 38,323	$ 7,072,159	$ 9,732,598	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002379				$ 1,999,773	$ 9,732,598	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR02380				$ 640,675	$ 9,732,598	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR04432	Vanderbilt University Medical Center	TR04432		$ 19,270	$ 9,732,598	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR04626	Children's Hospital of Philadelphia	TR04626		$ 721	$ 9,732,598	RESEARCH AND DEVELOPMENT	472,270,751
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD38208				$ 950,871	$ 950,871	RESEARCH AND DEVELOPMENT	472,270,751
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA246568			$ 166,133	$ 455,341	$ 953,544	RESEARCH AND DEVELOPMENT	472,270,751
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA252973	University of New Mexico	CA252973		$ 498,203	$ 953,544	RESEARCH AND DEVELOPMENT	472,270,751
NURSING RESEARCH	93.361	NR020362			$ 72,053	$ 286,751	$ 650,385	RESEARCH AND DEVELOPMENT	472,270,751
NURSING RESEARCH	93.361	NR18832				$ 159,172	$ 650,385	RESEARCH AND DEVELOPMENT	472,270,751
NURSING RESEARCH	93.361	NR21634			$ 5,899	$ 204,462	$ 650,385	RESEARCH AND DEVELOPMENT	472,270,751
21ST CENTURY CURES ACT - PRECISION MEDICINE INITIATIVE	93.368	OD39849				$ 5,674,822	$ 5,674,822	RESEARCH AND DEVELOPMENT	472,270,751
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)	93.384	140D042490004			$ 3,725,297	$ 8,537,494	$ 10,563,554	RESEARCH AND DEVELOPMENT	472,270,751
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)	93.384	D24AC00345	Columbia University Medical Center	D24AC00345		$ 1,374,177	$ 10,563,554	RESEARCH AND DEVELOPMENT	472,270,751
ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (ARPA-H)	93.384	D24AC00358	University Illinois-Urbana Champaign	D24AC00358		$ 651,883	$ 10,563,554	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA132878				$ 469,521	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA167551	University of Melbourne	CA167551		$ 157,290	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA195568			$ 951,318	$ 1,595,786	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA201179	Arizona State University	CA201179		$ 46,410	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217889			$ 55,261	$ 83,695	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225662				$ 21,724	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233432	Kaiser Foundation Research Ins	CA233432		$ 40,640	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233610			$ 71,327	$ 290,162	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA233700				$ 25	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA235026				$ 1,480	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237398				$ 63,747	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA244670	University of Washington	CA244670		$ 13,092	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA246510	St. Jude Children's Research Hospital	CA246510		$ 25,517	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA246585	University of Colorado Denver	CA246585		$ 8,457	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA247642	Alaska Native Tribal Health Consortium	CA247642		$ 14,417	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA248288			$ 184,316	$ 835,776	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA252060			$ 12,914	$ 592,303	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA253187				$ 742,188	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA254951				$ 599,351	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA255082	University of Washington	CA255082		$ 121,332	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258058			$ 163,851	$ 238,622	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA258119	University of Vermont	CA258119		$ 296	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA259201				$ 441,165	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA26211	University of Wisconsin-Madison	CA26211		$ 17,332	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262265	Tufts Medical Center	CA262265		$ 131,816	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA262393			$ 100,829	$ 629,273	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA264600				$ 244,121	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA265050				$ 540,715	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA268678	Collinge and Associates, Inc	CA268678		$ 254,261	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269264			$ 198,257	$ 543,560	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269617	NYU Grossman School of Medicine	CA269617		$ 38,321	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA269832	Ohio State University	CA269832		$ 239,010	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA271014			$ 72,432	$ 732,930	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA271503			$ 159,667	$ 510,180	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272473			$ 99,817	$ 570,652	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272668				$ 392,807	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA272883				$ 464,676	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA274970			$ 457,750	$ 698,436	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275065			$ 100,350	$ 446,533	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275074			$ 334,588	$ 675,437	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA275085	Arizona State University	CA275085		$ 80,181	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA277825				$ 677,708	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA282702			$ 80,346	$ 241,738	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA284748	University of Pennsylvania	CA284748		$ 51,114	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA285866	University of Southern California	CA285866		$ 9,068	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA288625	University of Michigan	CA288625		$ 5,400	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA289268	University of Washington	CA289268		$ 1,043	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA289560				$ 21,521	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA289606	Columbia University Medical Center	CA289606		$ 81,810	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA290675	University of Minnesota	CA290675		$ 23,245	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA290996				$ 27,956	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA292771	Northwestern University	CA292771		$ 5,651	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA294563				$ 583,967	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA298083				$ 86,689	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA298963	St. Jude Children's Research Hospital	CA298963		$ 43,789	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA299472	H. Lee Moffit Cancer Center & Research Institute	CA299472		$ 2,484	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA301086	Arizona State University	CA301086		$ 9,915	$ 15,486,335	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA168762				$ 189,569	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193478	St. Jude Children's Research Hospital	CA193478		$ 5,000	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196171	Washington University in St. Louis	CA196171		$ 390,571	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196171	Washington University in St. Louis	CA196171		$ 32,202	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA210138			$ 239,835	$ 800,252	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214679				$ 404,238	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA223481	University of Wisconsin-Madison	CA223481		$ 14,486	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA234428	Thomas Jefferson University	CA234428		$ 57,865	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237602			$ 84,552	$ 155,655	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA237659	University of Pennsylvania	CA237659		$ 163	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA238926				$ 11,690	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239164				$ 48,984	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239200			$ 104,348	$ 401,288	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA239548				$ 283,107	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA241164				$ 510,301	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246665	Public Health Institute	CA246665		$ 2,757	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA246704	Northwestern University	CA246704		$ 1,187	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA247606	Barrow Neurological Institute	CA247606		$ 54,572	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA249992	Emory University	CA249992		$ 26,744	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251065	University of Iowa	CA251065		$ 116,995	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA251801			$ 167,081	$ 588,593	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA256969	Fred Hutchinson Cancer Research Center	CA256969		$ 152,001	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA257558			$ 264,433	$ 474,778	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA258465			$ 191,161	$ 498,368	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA260259			$ 17,602	$ 748,083	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA264992	MD Anderson Cancer Center	CA264992		$ 189,946	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265879	Rhode Island Hospital	CA265879		$ 167,342	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA265945	University of Minnesota	CA265945		$ 11,347	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA268452	Rush River Research Corp.	CA268452		$ 2,682	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271402	Washington University in St. Louis	CA271402		$ 40,511	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA271410			$ 37,776	$ 797,893	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272271	University Illinois-Urbana Champaign	CA272271		$ 66,561	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA272628			$ 212,300	$ 475,823	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA274496				$ 808,867	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA275508	SonALAsense, Inc.	CA275508		$ 50,858	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA276174	Washington University in St. Louis	CA276174		$ 25,695	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA277138				$ 154,101	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA279629	Indiana University	CA279629		$ 100,233	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA279916				$ 239,464	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA280151	Case Western Reserve University	CA280151		$ 11,082	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA283663			$ 21,094	$ 545,652	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA284268	Johns Hopkins University	CA284268		$ 169,168	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA286127	Washington University in St. Louis	CA286127		$ 249,042	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA288396	Arizona State University	CA288396		$ 101,378	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA289249			$ 120,563	$ 415,970	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA289381	Medical University of South Carolina	CA289381		$ 93,579	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA292129	University of Arizona	CA292129		$ 30,999	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA292132				$ 12,975	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA296671				$ 192,883	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA299358				$ 13,428	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA86368	University of TX MD Anderson Cancer Center	CA86368		$ 104,688	$ 11,041,616	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	A022001	Alliance for Clinical Trials in Oncology	A022001		$ 36	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	A032303	Alliance for Clinical Trials in Oncology	A032303		$ 6,679	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	A071102	Alliance for Clinical Trials in Oncology	A071102		$ 2,159	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	A082101	Alliance for Clinical Trials in Oncology	A082101		$ 10,499	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	A11104	Brigham & Women's Hospital	A11104		$ 2,161	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	A151216A	Alliance for Clinical Trials in Oncology	A151216A		$ 457	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	AALL1732	National Clinical Trials Network	AALL1732		$ 1	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	AALL2131	National Clinical Trials Network	AALL2131		$ 1,604	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	AAML1831	National Clinical Trials Network	AAML1831		$ 8,049	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	ACCL1931	Children's Oncology Group	ACCL1931		$ 2,978	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	ACNS2031	Children's Oncology Group	ACNS2031		$ 4,180	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	ARAR2331	Children's Oncology Group	ARAR2331		$ 1,604	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	AREN2231	Children's Oncology Group	AREN2231		$ 4,771	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA108671	Icahn School of Medicine	CA108671		$ 402,954	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA13650	ECOG Research and Education Foundation, Inc.	CA13650		$ 1,692	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180790	Alliance for Clinical Trials in Oncology	CA180790		$ 105,035	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180820	ECOG Research and Education Foundation, Inc.	CA180820		$ 33,004	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180821	Brigham & Women's Hospital	CA180821		$ 515,189	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180868	NRG Oncology Foundation, Inc.	CA180868		$ 17,808	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180882			$ 560,859	$ 8,267,084	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180886	Children's Hospital of Philadelphia	CA180886		$ 127,957	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA180888	Oregon Health & Science University	CA180888		$ 25,958	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA186101	siRNAx, Inc.	CA186101		$ 3,563	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA186686	National Cancer Institute	CA186686		$ 1,562	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA186709	Dana-Farber Cancer Institute	CA186709		$ 899,460	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA189823	Alliance Foundation Trials, LLC	CA189823		$ 48,573	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA189955	Children's Hospital of Philadelphia	CA189955		$ 5,365	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA189955	Children's Hospital of Philadelphia	CA189955		$ 33,820	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA195946	Modulation Therapeutics	CA195946		$ 6,420	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA196854	Children's Hospital of Philadelphia	CA196854		$ 8,117	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA205406	Dana-Farber Cancer Institute	CA205406		$ 52,712	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA207183				$ 3,699	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA214890	University of Rochester Medical Center	CA214890		$ 5,482	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA217591	Syntrix Biosystems, Inc.	CA217591		$ 19,902	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA225996				$ 25,492	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA228823	Public Health Institute	CA228823		$ 93,284	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA229560				$ 36,083	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA232760	National Clinical Trials Network	CA232760		$ 25,329	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA232760	National Clinical Trials Network	CA232760		$ (129,098)	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA232760				$ 870,843	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA233332	Sloan-Kettering Institute for Cancer Research	CA233332		$ 164,920	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA233878	Northwestern University	CA233878		$ 97,434	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA243078	Translational Genomics Research Institute	CA243078		$ 34,947	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA248064				$ 409,091	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA248147			$ 12,496	$ 269,486	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA249929	University of Pennsylvania	CA249929		$ 51,185	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA25224	National Cancer Institute	CA25224		$ 1,021	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA255176	Louisiana State University and A&M College	CA255176		$ 44,215	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA256927				$ 244,764	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA258239				$ 290,861	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA261854				$ 306,836	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA262613				$ 425,343	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA263003				$ 44,418	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA264362			$ 594,072	$ 1,608,462	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA266344			$ 32,998	$ 668,289	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA266999				$ 98,349	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA268286	Oleolive, LLC	CA268286		$ 5,432	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA269384				$ 397,569	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA269568	University of Alabama at Birmingham	CA269568		$ 1,062	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA270380				$ 33,902	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA271431			$ 284,023	$ 530,757	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA272064	Modulation Therapeutics	CA272064		$ 109,843	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA272257			$ 524,598	$ 807,307	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA272426				$ 600,557	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA272496				$ 285,234	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA274985				$ 771,169	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER TREATMENT RESEARCH	93.395	CA275870				$ 661,029	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA276005				$ 477,850	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA276313				$ 1,191,445	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA276851			$ 77,749	$ 613,386	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA277853	Emmyon, Inc.	CA277853		$ 203,332	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA278184	Trekka Therapeutics LLC	CA278184		$ 3,795	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA278197	Washington University in St. Louis	CA278197		$ 43,196	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA278293	Myosin Therapeutics	CA278293		$ 391,124	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA278773				$ 149,228	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA278908				$ 813,396	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA280134			$ 117,879	$ 475,356	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA280999				$ 478,508	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA281707	NanoValent Pharmaceutical Inc.	CA281707		$ 50,625	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA282040	Wayne State University	CA282040		$ 6,298	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA282756	NYU Grossman School of Medicine	CA282756		$ 319,362	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA282979				$ 182,808	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA283479				$ 423,283	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA285345			$ 31,416	$ 491,868	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA285439			$ 46,848	$ 424,487	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA285536				$ 487,077	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA285925	Medical College of Wisconsin	CA285925		$ 214,067	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA286349				$ 154,722	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA286864				$ 562,893	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA288753				$ 545,669	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA288808				$ 73,516	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA288862				$ 576,821	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA288898				$ 9,714	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA289285				$ 664,708	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA291823				$ 172,828	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA292932	Fred Hutchinson Cancer Research Center	CA292932		$ 111,809	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA294704				$ 921,774	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA295558			$ 68,337	$ 327,741	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA302968				$ 79,771	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CA84203	Massachusetts General Hospital	CA84203		$ 522,305	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CCTG-NE1	Canadian Cancer Clinical Trials Group	CCTG-NE1		$ 24,991	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	CTIU2317-A082304	Alliance for Clinical Trials in Oncology	CTIU2317-A082304		$ 3,203	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	EA3231	ECOG-ACRIN Cancer Research Group	EA3231		$ 16,992	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	EA4232	ECOG-ACRIN Cancer Research Group	EA4232		$ 6,750	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	ECOG #6	Frontier Science & Technology	ECOG #6		$ 20,251	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	ECOGE1412	National Cancer Institute	ECOGE1412		$ 172	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	GOG 0244	National Cancer Institute	GOG 0244		$ 7,168	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	GOG-0286B	National Cancer Institute	GOG-0286B		$ 3,210	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	MM1YA-S01	SWOG Cancer Research Network	MM1YA-S01		$ 35,303	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	N1048	National Clinical Trials Network	N1048		$ 39	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	NRG-CC005	NRG Oncology Foundation, Inc.	NRG-CC005		$ 9,012	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	NRG-HN014	NRG Oncology Foundation, Inc.	NRG-HN014		$ 15,810	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	NRG-LU008	NRG Oncology Foundation, Inc.	NRG-LU008		$ 18,560	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	NRG-NH014	NRG Oncology Foundation, Inc.	NRG-NH014		$ 1,604	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	NSABP B-49	NSABP Foundation, Inc.	NSABP B-49		$ 57	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	RTOG1216	Alliance for Clinical Trials in Oncology	RTOG1216		$ 37,886	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	SWOG S0931	National Cancer Institute	SWOG S0931		$ 652	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER TREATMENT RESEARCH	93.395	WF2304-A172401	Wake Forest University	WF2304-A172401		$ 2,408	$ 32,884,779	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA220378				$ 5,913	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA233790				$ 82,918	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA238720	Massachusetts Institute of Technology	CA238720		$ 83,595	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA239726				$ 366,977	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA240323				$ 214,606	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA241123	University at Buffalo	CA241123		$ 60,130	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA242023				$ 206,615	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA247929				$ 402,609	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA248019	Case Western Reserve University	CA248019		$ 16,351	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA248298				$ 249,554	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA249116				$ 529,452	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA250481			$ 189,921	$ 406,097	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA251443	University of New South Wales	CA251443		$ 19,651	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA254849	University of Minnesota	CA254849		$ 23,374	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CANCER BIOLOGY RESEARCH	93.396	CA254961				$ 100,246	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA255068				$ 394,498	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA256481	University Illinois-Urbana Champaign	CA256481		$ 55,911	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA258274			$ 141,367	$ 362,488	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA261925				$ 500,994	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA261932				$ 379,419	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA264048			$ 99,700	$ 830,337	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA265892	Joan & Sanford I. Weill Medical	CA265892		$ 13,918	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA266113			$ 45,356	$ 358,345	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA269075	The Research Foundation SUNY	CA269075		$ 455,140	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA269295				$ 537,120	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA271486			$ 67,073	$ 465,158	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA272602				$ 351,897	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA273027				$ 623,967	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA276047				$ 421,589	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA278050				$ 242,848	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA278300	H. Lee Moffit Cancer Center & Research Institute	CA278300		$ 1,271	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA279065	Mercy Children's Hospital	CA279065		$ 52,382	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA282451	Brigham & Women's Hospital	CA282451		$ 142,949	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA283317			$ 320,064	$ 916,838	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA283539				$ 194,860	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA284153				$ 164,522	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA290468				$ 361,190	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA294653				$ 530,971	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA300681	Sanford Research	CA300681		$ 11,451	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER BIOLOGY RESEARCH	93.396	CA81436				$ 215	$ 11,138,366	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA116201			$ 130,800	$ 2,510,333	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA136393			$ 376,530	$ 2,131,775	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA15083				$ 1,796,354	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA186781			$ 77,991	$ 1,970,147	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA210964			$ 450,891	$ 2,474,424	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA272170	University of Michigan	CA272170		$ 73,702	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA274504			$ 388,709	$ 807,331	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CENTERS SUPPORT GRANTS	93.397	CA283114	Massachusetts Institute of Technology	CA283114		$ 137,687	$ 11,901,753	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA230193				$ 131,255	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA237875				$ 6,141	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA248972	University of Florida	CA248972		$ 19,050	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA252044				$ 339,794	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA252178				$ 39,123	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA273304				$ 115,241	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA279652				$ 210,735	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA286969				$ 79,493	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA287495				$ 52,868	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA294616				$ 19,191	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA294722				$ 24,330	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER RESEARCH MANPOWER	93.398	CA90628				$ 656,742	$ 1,693,963	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CONTROL	93.399	CA189823	Alliance Foundation Trials, LLC	CA189823		$ 1,658,570	$ 1,835,349	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CONTROL	93.399	CA189955	Children's Hospital of Philadelphia	CA189955		$ 4,772	$ 1,835,349	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CONTROL	93.399	CA242635	University of Wisconsin-Madison	CA242635		$ 137,652	$ 1,835,349	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CONTROL	93.399	CA242643	Northwestern University	CA242643		$ 805	$ 1,835,349	RESEARCH AND DEVELOPMENT	472,270,751
CANCER CONTROL	93.399	CA274374	Fred Hutchinson Cancer Research Center	CA274374		$ 33,550	$ 1,835,349	RESEARCH AND DEVELOPMENT	472,270,751
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPHF0006	Indiana University	90DPHF0006		$ 1,509	$ 425,867	RESEARCH AND DEVELOPMENT	472,270,751
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0017	Craig Hospital	90DPTB0017		$ 9,013	$ 425,867	RESEARCH AND DEVELOPMENT	472,270,751
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH	93.433	90DPTB0031				$ 415,345	$ 425,867	RESEARCH AND DEVELOPMENT	472,270,751
PREVENTION AND PUBLIC HEALTH FUND (AFFORDABLE CARE ACT): ENHANCED SURVEILLANCE FOR NEW VACCINE PREVENTABLE DISEASE	93.533	HL146114				$ 760,369	$ 760,369	RESEARCH AND DEVELOPMENT	472,270,751
PUBLIC HEALTH RESPONSE, FORECASTING, AND ANALYTIC CAPACITIES RELATED TO DISEASE OUTBREAKS, EPIDEMICS, AND PANDEMICS	93.823	FT000003	University of Minnesota	FT000003		$ 190,177	$ 190,177	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	CRB-SSS-S-21-006050	Social & Scientific Systems	CRB-SSS-S-21-006050		$ 25,354	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL07111				$ 211,000	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL105907	NYU Grossman School of Medicine	HL105907		$ 300	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107304				$ 472,791	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL117913				$ 566,603	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL133501			$ 362,954	$ 533,360	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134864				$ 76,880	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136348				$ 2,446	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140411			$ 88,670	$ 608,075	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142068				$ 274,418	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142627				$ 213,237	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL144529			$ 19,020	$ 145,192	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145268			$ 107,115	$ 709,782	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148144				$ 107,330	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148339				$ 271,254	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149409	Case Western Reserve University	HL149409		$ 27,491	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL150086				$ 342,689	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151351	Leland Stanford Junior University	HL151351		$ 27,519	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL151379				$ 555,552	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155396	Duke University	HL155396		$ 32,734	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155506				$ 163,368	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL155834	University of Michigan	HL155834		$ 79,347	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156812	Duke University	HL156812		$ 28,203	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156855			$ 64,715	$ 645,104	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL157220	NYU Grossman School of Medicine	HL157220		$ 67,928	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158517				$ 444,401	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158548			$ 389,201	$ 844,072	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL158691			$ 79,284	$ 252,106	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL159216	Indiana University	HL159216		$ 11,430	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160226				$ 271,157	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160273	Northwestern University	HL160273		$ 191,683	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160730	University of California Los Angeles	HL160730		$ 13,927	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL160761				$ 611,787	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161169				$ 1,050,237	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161697	Beth Israel Deaconess Medical Center	HL161697		$ 18,140	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL161821				$ 475,457	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162747			$ 166,292	$ 615,853	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL162830				$ 530,524	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL163775	Oklahoma State University	HL163775		$ 14,644	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164140	Vivita Technologies, Inc.	HL164140		$ 133,298	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164416			$ 40,904	$ 523,512	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL164520				$ 797,413	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165017	Duke University	HL165017		$ 445	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165065	Northwestern University	HL165065		$ 41,335	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL165176			$ 186,517	$ 446,413	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL166140			$ 59,497	$ 1,042,086	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL166204				$ 39,012	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL167811			$ 292,971	$ 441,608	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL167947	Massachusetts Institute of Technology	HL167947		$ 225,319	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL168392	Columbia University	HL168392		$ 10,330	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL168940	Duke University	HL168940		$ 62,081	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169268			$ 35,205	$ 840,446	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169320				$ 605,833	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL169345	Stanford University	HL169345		$ 83,332	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL170019	University of Miami	HL170019		$ 53,479	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL170507				$ 42,071	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171023				$ 426,610	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171097			$ 558	$ 560,140	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171158	Miriam Hospital	HL171158		$ 19,229	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL171715	Nationwide Children's Hospital	HL171715		$ 57,615	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL172784			$ 193,446	$ 700,137	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL173523	Vanderbilt University Medical Center	HL173523		$ 72,462	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL173775				$ 258,823	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL174650				$ 55,195	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL174785				$ 537,109	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL175086				$ 788,170	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL175205				$ 55,999	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL175879	University of Michigan	HL175879		$ 84,413	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL176491				$ 160,344	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL176555				$ 330,878	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL177037				$ 52,604	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL177055	Columbia University	HL177055		$ 40,625	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL177853				$ 13,875	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL179093				$ 295,009	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL1798131	U.T. Southwestern Medical Center	HL1798131		$ 76,023	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL180379				$ 139,893	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL180393				$ 129,062	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL7111				$ 128,849	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL81753			$ 103,899	$ 450,577	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL84155				$ 314,183	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL88942	Icahn School of Medicine	HL88942		$ 69,615	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL92621				$ 78,508	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL96812	NYU Grossman School of Medicine	HL96812		$ 107,935	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL98967				$ 983,874	$ 23,909,144	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL126667				$ 14,140	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL138998	University of North Carolina at Chapel Hill	HL138998		$ 16,845	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL139054	University of Arizona	HL139054		$ 16,914	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL141722	Stanford University	HL141722		$ 213,855	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL142269	University of Pennsylvania	HL142269		$ 13,374	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL142933			$ 17,263	$ 165,185	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL142992			$ 127,215	$ 443,457	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL145265	University of Michigan	HL145265		$ 8,389	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL146002	Brigham & Women's Hospital	HL146002		$ 6,535	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL146705	North Dakota State University	HL146705		$ 34,749	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL146741				$ 6,701	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL147261	University of Michigan	HL147261		$ 5,283	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL148437	National Jewish Health	HL148437		$ 58,061	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL151671				$ 177,529	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL151865	University of Colorado	HL151865		$ 38,737	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL152967			$ 142,410	$ 322,617	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL153407				$ 607,295	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL153519	University of Michigan	HL153519		$ 2,700	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL155410	Stanford University	HL155410		$ 71,196	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL156812	Duke University	HL156812		$ 2,446,672	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL157424	National Jewish Health	HL157424		$ 256,474	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL157984				$ 76,044	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL158287	University of Arizona	HL158287		$ 275,447	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL158507	Indiana University	HL158507		$ 8,009	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL158532			$ 171,695	$ 430,531	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL158811			$ 73,924	$ 431,029	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL159997	University of Pennsylvania	HL159997		$ 17,876	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL160545				$ 87	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL160570			$ 97,318	$ 398,510	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL161362	University of California San Diego	HL161362		$ 322,137	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL161674			$ 10,868	$ 470,787	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL161804	Sanford-Burnham Medical	HL161804		$ 134,955	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL161841	Massachusetts General Hospital	HL161841		$ 2,359,552	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL161847	Massachusetts General Hospital	HL161847		$ 4,580,965	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL162169	Shape Medical Systems, Inc.	HL162169		$ 1,683	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL162828				$ 842,692	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL164901				$ 202,668	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL166187				$ 638,445	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL166402	University of Maryland	HL166402		$ 182,123	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL166785	Beth Israel Deaconess Medical Center	HL166785		$ 205	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL167796				$ 670,329	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL168212				$ 147,181	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL169382				$ 561,961	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL169759	Oregon Health & Science University	HL169759		$ 42,084	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL170802	Minnesota HealthSolutions Corp	HL170802		$ 51,772	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL170961	University of Virginia	HL170961		$ 278,552	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL171056			$ 904	$ 547,683	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL171137	University of Wisconsin-Madison	HL171137		$ 566	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL171245	North Dakota State University	HL171245		$ 46,093	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL171508				$ 44,890	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL171782	University of Vermont	HL171782		$ 1,149	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
LUNG DISEASES RESEARCH	93.838	HL171915	Lundquist Institute for Biomedical Innovation at Harbor	HL171915		$ 169,948	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL173214				$ 436,075	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL174505				$ 714,135	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL175907				$ 72,745	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL176373	Glycodots, LLC.	HL176373		$ 79,691	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL176414				$ 170,587	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL177837	Case Western Reserve University	HL177837		$ 123,706	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL56470			$ 304,937	$ 635,066	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL62150				$ 611,036	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	HL92961				$ 460,105	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
LUNG DISEASES RESEARCH	93.838	RTI 22-312-0217571-66178	Columbia University Medical Center	RTI 22-312-0217571-66178		$ 141,513	$ 22,307,320	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1101	National Marrow Donor Program	BMT CTN 1101		$ 12,932	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1102	National Marrow Donor Program	BMT CTN 1102		$ 6,102	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1501	National Marrow Donor Program	BMT CTN 1501		$ 11,884	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	BMT CTN 1506	National Marrow Donor Program	BMT CTN 1506		$ 1,092	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL130724	Versiti Blood Health, Inc.	HL130724		$ 20,730	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL138645	Icahn School of Medicine	HL138645		$ 19,410	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL140097	Cleveland Clinic Foundation	HL140097		$ 17,993	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL141112				$ 227,364	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL142389	Syntrix Biosystems, Inc.	HL142389		$ 126,496	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147734	Retham Technologies	HL147734		$ 56,529	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147852				$ 1,255	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL147894	University of Washington	HL147894		$ 15,338	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL148762	University of Pittsburgh	HL148762		$ 175	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL153310				$ 166,530	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL157401	University of Alabama at Birmingham	HL157401		$ 9,825	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL158932				$ 309,650	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL162729			$ 126,956	$ 645,361	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL166238			$ 145,056	$ 236,370	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL167354				$ 336,278	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL167668	Versiti Blood Health, Inc.	HL167668		$ 8,199	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL169944	Vanderbilt University Medical Center	HL169944		$ 11,229	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL171911				$ 150,710	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL172948			$ 91,987	$ 389,311	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL174922	University of Louisville Research Foundation	HL174922		$ 25,037	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL176351	SanaHeal	HL176351		$ 100,917	$ 2,906,717	RESEARCH AND DEVELOPMENT	472,270,751
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL151662				$ 786	$ 358,035	RESEARCH AND DEVELOPMENT	472,270,751
TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS	93.840	HL158287	University of Arizona	HL158287		$ 357,249	$ 358,035	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR056950				$ 499,016	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR077538			$ 247,497	$ 573,739	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078552				$ 351,451	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR56212				$ 531,331	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR73147				$ 3,186	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR74395				$ 37,268	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR75037				$ 274,306	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76028				$ 204,706	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76144	University of Pittsburgh	AR76144		$ 826	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76312			$ 150,000	$ 801,142	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76339				$ 609,886	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76347			$ 14,854	$ 725,387	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR76568	University of Pittsburgh	AR76568		$ 8,764	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77360	Johns Hopkins University	AR77360		$ 8,004	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR77518				$ 203,800	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78073	University of Michigan	AR78073		$ 1,480	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78254				$ 186,885	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78389	University of California Irvine	AR78389		$ 45,949	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR78924	Rhode Island Hospital	AR78924		$ 2,580	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR80377	Population Health Research Institute	AR80377		$ 63,334	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR80993	Johns Hopkins University	AR80993		$ 2,874	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81040	Maine Medical Center	AR81040		$ 139,991	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81318				$ 456,879	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81382	University of Texas Health at Houston	AR81382		$ 6,785	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81788	University of Michigan	AR81788		$ 230,522	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR81898				$ 1,097	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR82227				$ 26,802	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR83873				$ 152,292	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84053	Arizona State University	AR84053		$ 2,880	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84101				$ 18,875	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84126				$ 170,192	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84242				$ 598	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84283				$ 181,615	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR84831				$ 651,747	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR85016				$ 293,314	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR85562				$ 18,630	$ 7,488,133	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	APOL1	University of Miami	APOL1		$ 939	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07013				$ 16,619	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07198				$ 338,114	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK07352				$ 277,243	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100846	University of Pennsylvania	DK100846		$ 358	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101405				$ 28,101	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK104162	Beckman Research Institute of the City of Hope	DK104162		$ 20,949	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106993	University of South Florida	DK106993		$ 7,606	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK107733	University of TX SW Medical Center	DK107733		$ 77,873	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288	University of Texas MD Anderson Cancer Center	DK108288		$ 722	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108288				$ 423,813	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK110986	Washington University in St. Louis	DK110986		$ 48,182	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111378				$ 424,883	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114007				$ 611,161	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114786	Children's Hospital of Philadelphia	DK114786		$ 15,074	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575			$ 66,791	$ 98,502	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115575	University of North Carolina at Chapel Hill	DK115575		$ 488,658	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116092	University of Wisconsin-Madison	DK116092		$ 7,995	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116231				$ 391,970	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116743	Oregon Health & Science University	DK116743		$ 1,481	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117861				$ 330,505	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117910				$ 552,557	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118619				$ 434,545	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118761	American Gastroenterlogical Association	DK118761		$ 5,954	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120261	Oxalo Therapeutics, Inc.	DK120261		$ 1,013	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120559				$ 23,309	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK120890	Temple University Hospital	DK120890		$ 12,338	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121204				$ 370,450	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121330	University of Texas Health at Houston	DK121330		$ 27,682	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122603	JAEB Center for Health Research, Inc.	DK122603		$ 1,769	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122734				$ 438	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122948				$ 585,488	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123441	Arizona State University	DK123441		$ 48,386	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK123549				$ 557,635	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124182				$ 114,073	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124190				$ 204,490	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124358				$ 16,393	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125243	Adva-tec, Inc.	DK125243		$ 7,055	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125252				$ 5,425	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125431	University of Minnesota	DK125431		$ 10,098	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK125692	University of Alabama	DK125692		$ 20,094	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126110	University of Maryland-Baltimore	DK126110		$ 62,297	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126206				$ 432,246	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126662				$ 411,985	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126691			$ 13,712	$ 72,760	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126827				$ 168,674	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127064				$ 140,738	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127157	University of North Carolina at Chapel Hill	DK127157		$ 1,558	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127564				$ 27,149	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127978				$ 230,872	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127992				$ 239,544	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK127998				$ 360,668	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128017				$ 352,819	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128842	University of Colorado	DK128842		$ 21,661	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK128913				$ 49,655	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129191	University of Colorado	DK129191		$ 16,521	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129205				$ 473,676	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129208				$ 118,673	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129240			$ 23,108	$ 358,536	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129241				$ 206,931	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129259	University of Colorado	DK129259		$ 103,527	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129297				$ 475,140	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129315			$ 17,249	$ 172,130	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129541	University of Florida	DK129541		$ 32,133	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129564	Virginia Commonwealth University	DK129564		$ 121,849	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129616	Yale University	DK129616		$ 63,094	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129708				$ 185,481	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK129886				$ 48,487	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130181				$ 232,143	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130331				$ 540,992	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130566			$ 170,056	$ 350,694	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130854				$ 295,890	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK130884				$ 479,069	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131133	University Illinois-Urbana Champaign	DK131133		$ 6,459	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131338				$ 132,470	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131455				$ 346,050	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131586	University of Pittsburgh	DK131586		$ 13,644	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131685				$ 468,161	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK131946				$ 279,521	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132001	University of North Carolina at Chapel Hill	DK132001		$ 18,224	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132046	University of Minnesota	DK132046		$ 177,064	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132651				$ 544,259	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132709	Indiana University	DK132709		$ 25,474	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132718				$ 314,858	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK132733	Massachusetts General Hospital	DK132733		$ 14,327	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133171				$ 438,811	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133194			$ 38,261	$ 388,024	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133401				$ 615,946	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133643				$ 145,293	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133897				$ 249,649	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK133947	University of Chicago	DK133947		$ 591,367	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134321	Northwestern University	DK134321		$ 51,699	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134366				$ 623,456	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134448				$ 599,820	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134482	Hennepin Healthcare Research Institute	DK134482		$ 97,219	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134661			$ 170,623	$ 365,990	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134759				$ 85,927	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134765				$ 137,061	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134767				$ 255,969	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK134815	University Texas Medical Branch	DK134815		$ 8,570	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135097				$ 394,764	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135200				$ 91,681	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135407				$ 1,000,333	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135440				$ 614,827	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK135573	University of Arizona	DK135573		$ 241	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136007	University of Wisconsin-Madison	DK136007		$ 16,190	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136208				$ 436,974	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136511				$ 316,717	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136731				$ 482,721	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK136906			$ 126,537	$ 529,502	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137231			$ 93,558	$ 552,503	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137520	Seattle Children's Hospital	DK137520		$ 28,678	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137533	Vanderbilt University Medical Center	DK137533		$ 37,334	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137778				$ 2,573	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137790	University of Louisville Research Foundation	DK137790		$ 4,305	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137800				$ 400,331	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137827				$ 286,489	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK137868			$ 109,915	$ 383,329	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138619	Phenomix Sciences	DK138619		$ 1,062,477	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138638				$ 53,103	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138818				$ 859,348	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138901	University of Pennsylvania	DK138901		$ 19,509	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138915	University of Colorado	DK138915		$ 37,925	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK138998				$ 406,331	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139028				$ 832,094	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139207				$ 510,070	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139233				$ 46,999	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139558	Yale University	DK139558		$ 51,582	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139604				$ 306,012	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139607				$ 547,433	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK139817	PAVAJ Vascular Corporation	DK139817		$ 6,183	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140206				$ 108,965	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140734	Nemours Children's Health	DK140734		$ 14,575	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140865	Vanderbilt University Medical Center	DK140865		$ 6,414	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK140921				$ 276,104	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141297	HydroGene Therapeutics	DK141297		$ 83,236	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141438				$ 30,487	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141633				$ 11,097	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141679				$ 183,344	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141803	Vanderbilt University Medical Center	DK141803		$ 9,346	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141902				$ 26,550	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK141911				$ 145,752	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK142200	Emmyon, Inc.	DK142200		$ 117,642	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK142564	Endotat Biotechnologies, LLC	DK142564		$ 100,807	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK142606				$ 182,983	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK142878				$ 37,406	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK143937				$ 18,423	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK144863				$ 25,595	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK144994				$ 43,836	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK145067				$ 22,658	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK147565				$ 16,610	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK29953	University of Alabama at Birmingham	DK29953		$ 22,793	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK40484				$ 685,697	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK44650				$ 18,419	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK45343				$ 255,999	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK52766			$ 14,016	$ 365,681	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57061				$ 560,921	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK57993				$ 76,906	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK58816				$ 814,558	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59597				$ 617,182	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK59615				$ 84,079	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK73983				$ 260,534	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK74008	Johns Hopkins University	DK74008		$ 372,100	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78646			$ 24,891	$ 696,573	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK78924				$ 150,601	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK83912	University of Michigan	DK83912		$ 16,866	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567	Case Western Reserve University	DK84567		$ (1,136)	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK84567				$ 1,153,481	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK90358			$ 35,502	$ 837,206	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK92255				$ 63,303	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK94157	Case Western Reserve University	DK94157		$ 214,471	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98085	Beckman Research Institute of the City of Hope	DK98085		$ 9,998	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK98468			$ 20,000	$ 500,521	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99160				$ 349,299	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	HL170504	University of Minnesota	HL170504		$ 881	$ 40,360,165	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS092882				$ 767,727	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS097876	Columbia University	NS097876		$ 3,250	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS100620				$ 2,161,923	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS102289	University of Cincinnati	NS102289		$ 559	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS103212				$ 564,717	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110085				$ 151,890	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110114	Endomimetics, LLC	NS110114		$ 39,698	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110435			$ 268,751	$ 1,118,182	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS110772	University of Cincinnati	NS110772		$ 20,295	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS111039	Duke University	NS111039		$ 30,673	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112144				$ 165,034	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112153				$ 384,125	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112497			$ 95,868	$ 95,868	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS112826	Yale School of Medicine	NS112826		$ 96,589	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113637	University California San Francisco	NS113637		$ 91,735	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113724	Evogen, Inc.	NS113724		$ 148	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113760				$ 206,321	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113803				$ 366,525	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS113851	Northwestern University	NS113851		$ 4,202	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114147			$ 127,743	$ 215,743	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS114552	University of Chicago	NS114552		$ 57,699	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115126				$ 173,219	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198				$ (26,561)	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115198	Mount Sinai School of Medicine	NS115198		$ 44,661	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115388	Massachusetts General Hospital	NS115388	$ 93,783	$ 3,578,594	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS115877			$ 9,771	$ 177,234	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117432			$ 32,877	$ 123,543	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117450	University of Cincinnati	NS117450		$ 38,034	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117461				$ 661,679	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117844	Ohio State University	NS117844		$ 106,496	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS117944			$ 14,462	$ 562,985	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118513			$ 209,730	$ 530,075	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS118669	Banner Sun Health Research Institute	NS118669		$ 20,000	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169	National Institute of Neurological Disorders and Stroke	NS119169		$ 15,917	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119169			$ 408,500	$ 765,766	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119587	Houston Methodist Research	NS119587		$ 4,408	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119714	Scripps Research	NS119714		$ 354	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119834	University of Texas Health at Houston	NS119834		$ 28,759	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS119974	Key Technologies, Inc.	NS119974		$ 4,731	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120331	St. Joseph's Hospital and Medical Center	NS120331		$ 16,943	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120496	University of California San Diego	NS120496		$ 60,612	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120871	University of Cincinnati	NS120871		$ 2,372	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120877				$ 589,768	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120901	Massachusetts General Hospital	NS120901		$ 266,976	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS120992				$ 609,850	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121075			$ 6,712	$ 231,883	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121125				$ 691,376	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121386	University of Florida	NS121386		$ 45,685	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS121928	Case Western Reserve University	NS121928		$ 26,351	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122096				$ 223,244	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122174				$ 865,816	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122226	Binghamton University	NS122226		$ 1,022	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122419	New York University	NS122419		$ 101,242	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122602	Piraeus Medical, Inc.	NS122602		$ 40,345	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS122764	Johns Hopkins University	NS122764		$ 3,117	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123052				$ 677,336	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123066				$ 441,464	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123743	Stanford University	NS123743		$ 307,522	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS123746	Icahn School of Medicine	NS123746		$ 40,695	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124065	University of Minnesota	NS124065		$ 182,138	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124613	University of Florida	NS124613		$ 53,460	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124650			$ 66,737	$ 241,212	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124688				$ 130,893	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS124911				$ 224,142	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125023	University of Cincinnati	NS125023		$ 15,845	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125417			$ 242,982	$ 1,252,077	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125437	University of Minnesota	NS125437		$ 157,413	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125597	University of Wisconsin-Eau Claire	NS125597		$ 20,618	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS125895	NaviNetics, Inc.	NS125895		$ 276,338	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126227				$ 448,777	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126406	University of California Los Angeles	NS126406		$ 173,708	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS126609	University of Minnesota	NS126609		$ 7,582	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127331				$ 205,537	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127849	Carnegie Mellon University	NS127849		$ 147,391	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS127922			$ 349,942	$ 672,108	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128071			$ 145,905	$ 414,826	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128199	Medical College of Wisconsin	NS128199		$ 4,222	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128212				$ 147,745	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128228	Duquesne University of the Holy Spirit	NS128228		$ 43,179	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128397	University Texas Medical Branch	NS128397		$ 40,970	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS128612			$ 412,498	$ 785,092	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129164	Washington University in St. Louis	NS129164		$ 133,562	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129549			$ 15,767	$ 521,833	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129622				$ 517,802	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS129671				$ 612,089	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS130297				$ 129,689	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS131636	University of Florida	NS131636		$ 5,778	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132128			$ 152,986	$ 358,946	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132146	Leland Stanford Junior University	NS132146		$ 10,229	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS132330			$ 250,353	$ 1,230,630	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS133986	Massachusetts General Hospital	NS133986		$ 1,400	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS133986				$ 375,185	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS134655	Yale University	NS134655		$ 376	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135130				$ 120,514	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135220	H. Lee Moffit Cancer Center & Research Institute	NS135220		$ 18,114	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135749	Conway Medical, LLC	NS135749		$ 148,624	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS135898				$ 47,797	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136020	Massachusetts General Hospital	NS136020		$ 186,203	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136021	Massachusetts General Hospital	NS136021		$ 27,468	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136022				$ 6,769,602	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136683	Shirley Ryan AbilityLab	NS136683		$ 151,264	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136792				$ 197,875	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS136939	St. Joseph's Hospital and Medical Center	NS136939		$ 153,039	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS137447				$ 811,323	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS137907			$ 14,965	$ 508,582	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS138003	Mount Sinai School of Medicine	NS138003		$ 21,125	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS138490				$ 113,179	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS139383	Boston University	NS139383		$ 106,833	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS139637				$ 26,951	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS141137	University of Miami	NS141137		$ 46,107	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS141217				$ 35,919	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS144593			$ 28,590	$ 146,703	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS145449				$ 20,902	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS31744				$ 337,438	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS65705	University California San Francisco	NS65705		$ 10,049	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS76491			$ 161,816	$ 362,486	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80165	University of Alabama at Birmingham	NS80165	$ 49,433	$ 69,875	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168	National Institute of Neurological Disorders and Stroke	NS80168		$ (13,431)	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS80168			$ 542,976	$ 1,127,134	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS84974			$ 1,075,567	$ 2,004,262	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS89757				$ 489,539	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92091	University of Miami	NS92091		$ 122,597	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS92625				$ 702,979	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS95495				$ 19,300	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS96761	Carnegie Mellon University	NS96761		$ 138,569	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97273				$ 153,050	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS97876	Columbia University	NS97876	$ 27,625	$ 88,573	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS	93.853	NS99043	University of Cincinnati	NS99043		$ 18,428	$ 43,428,180	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI104681	Duke University	AI104681		$ 474,803	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108682				$ 562,841	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108891				$ 769,090	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI108906				$ 534,198	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	Benaroya Research Institute at Virginia Mason	AI109565		$ 159,041	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI110173				$ 276,636	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI112844	University of Virginia School of Medicine	AI112844		$ 20,555	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116501	Washington University in St. Louis	AI116501		$ 11,720	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	Childrens Hospital Medical Center	AI117804		$ 33,919	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127365				$ 997	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI128729			$ 230,809	$ 430,208	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132165				$ 167,227	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI132348				$ 23,045	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134770	University of Massachusetts	AI134770		$ 30,074	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134937			$ 106,493	$ 234,595	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI138965				$ 235,303	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143882				$ 33,061	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144301	Joan & Sanford I. Weill Medical	AI144301		$ 5,707	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI145108	University of Maryland-Baltimore	AI145108		$ 14,425	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI147652				$ 85,982	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148963	Columbia University	AI148963		$ 10,890	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI150100				$ 67,616	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154470	Children's Hospital of Philadelphia	AI154470		$ 2,711	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154598	University of Virginia School of Medicine	AI154598		$ 20,555	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154659	Vanderbilt University Medical Center	AI154659		$ 6,947	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155378				$ 1,727	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI155752	Dartmouth College	AI155752		$ 118,174	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI158813				$ 232,481	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI159230				$ 3,641	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162678			$ 8,896	$ 357,591	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI162699	University of Minnesota	AI162699		$ 48,244	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI163081	Northwestern University	AI163081		$ 154,781	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI163090	Regents of the University of California at San Francisco	AI163090		$ 38,746	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI164562	Emory University	AI164562		$ 50,915	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI167700	Northeastern University	AI167700		$ 5,481	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI169530			$ 243,796	$ 590,379	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170424	Cedars Sinai Medical Center	AI170424		$ 84,299	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170478				$ 340,279	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170535				$ 552,658	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI170649				$ 579,691	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171008	University of Michigan	AI171008		$ 164,826	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171055	Children's Hospital of Philadelphia	AI171055		$ 9,954	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI171306				$ 395,258	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI172838			$ 167,437	$ 581,803	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175039				$ 57,601	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI175935	Oregon Health & Science University	AI175935		$ 20,475	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI177211	Johns Hopkins University	AI177211		$ 11,234	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI177472			$ 12,871	$ 181,612	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI177986	Oregon Health & Science University	AI177986		$ 4,207	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI178147				$ 132,572	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI178943				$ 160,096	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179331	Cactus Bio, LLC	AI179331		$ 12,362	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179609				$ 469,762	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179709			$ 11,047	$ 619,528	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI179974				$ 943,509	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI181542				$ 138,767	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI181754				$ 92,923	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI182489				$ 202,923	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI182888			$ 35,120	$ 155,138	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI183264	University of Arizona	AI183264		$ 35,315	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI183801				$ 290,753	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI184071	Massachusetts General Hospital	AI184071		$ 69,458	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI184121			$ 269,419	$ 524,522	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI184360				$ 399,189	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI186027	University of Massachusetts Amherst	AI186027		$ 69,248	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI186242				$ 31,723	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI187691				$ 22,047	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI188373				$ 102,799	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI193181				$ 54,776	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI33144				$ 54,869	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI68636	University of California Los Angeles	AI68636		$ 35,242	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI71106			$ 156,975	$ 570,739	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI82973	University California San Francisco	AI82973		$ 1,200	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI89714				$ 335,194	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI91594			$ 115,852	$ 298,726	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI176254				$ 133,246	$ 14,754,829	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM08685				$ 347,357	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132100				$ 14,874	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM135488				$ 43,387	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136262				$ 321,898	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136869				$ 236,776	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM140487				$ 385,185	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM141003			$ 242,150	$ 505,166	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM142122	Southcentral Foundation	GM142122		$ 46,513	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM142710				$ 541,656	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM143949				$ 411,483	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144233				$ 333,914	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144351			$ 79,920	$ 154,751	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM144393			$ 137,151	$ 294,983	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145385	University of North Florida	GM145385		$ 15,239	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM145408				$ 1,252,368	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM146651				$ 596,082	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM147134				$ 516,428	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM148971	University of North Carolina at Chapel Hill	GM148971		$ 20,930	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM150723				$ 281,708	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM154167	University of Southern California	GM154167		$ 7,878	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM155031				$ 479,658	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM55252				$ 21,856	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM75148				$ 264,750	$ 7,094,840	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	AR84222				$ 427,206	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100251	Sersense, Inc.	HD100251		$ 281,283	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD100540	Johns Hopkins University	HD100540		$ 160	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102615	Arizona State University	HD102615		$ 479,524	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102663				$ 220,853	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103099	Massachusetts General Hospital	HD103099		$ 18,099	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105714	University Kansas Medical Center	HD105714		$ 57,126	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD105892	Case Western Reserve University	HD105892		$ 18,054	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106096			$ 437,382	$ 799,799	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD106162				$ 83,501	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107034			$ 27,473	$ 287,705	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD107897	Sequitur Health Corporation	HD107897		$ 69,118	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD109127	Henry Ford Health System	HD109127		$ 42,107	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD110681	University of Minnesota	HD110681		$ 5,008	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD110981	University of Minnesota	HD110981		$ 20,177	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112161				$ 8,773	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112327			$ 206,250	$ 777,045	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112474	MaineHealth	HD112474		$ 151,328	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD112824	Louisiana State University Agricultural Center	HD112824		$ 975	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD113024	Ohio State University	HD113024		$ 12,997	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD115260	Brigham & Women's Hospital	HD115260		$ 66,476	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD115283			$ 489,409	$ 1,374,586	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD115297				$ 47,006	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD116629	Sequitur Health Corporation	HD116629		$ 81,999	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD116735	University of Kentucky Research Foundation	HD116735		$ 17,753	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD116957				$ 30,191	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD44763	University of Minnesota	HD44763		$ 51,745	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD84423	University Texas Medical Branch	HD84423		$ 157,372	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD86843	Spaulding Rehabilitation Hospital	HD86843		$ 102,877	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD87413	University of Virginia	HD87413		$ 2,410	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD96993	Sersense, Inc.	HD96993		$ 259,508	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD98269	University of Pennsylvania	HD98269		$ 650	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD99147			$ 623,345	$ 720,336	$ 6,673,747	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG03949	Albert Einstein College of Medicine	AG03949		$ 132,881	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG056366			$ 42,096	$ 1,059,674	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG058266			$ 10,993	$ 166,222	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG058812				$ 70,058	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG067593				$ 654,984	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG06786			$ 20,077	$ 345,673	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG078533	University of Texas at Austin	AG078533		$ 1,335	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG080037				$ 838,893	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG083832				$ 810,152	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG091264				$ 85,966	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG11378			$ 92,662	$ 737,632	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG23438	Washington University in St. Louis	AG23438		$ 90,681	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG24904	Northern CA Institute for Reseach & Education	AG24904		$ 1,780,608	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG27161	University of Wisconsin-Madison	AG27161		$ 84,435	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG32438	Washington University in St. Louis	AG32438		$ 133,125	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG37491				$ 519,369	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG44615				$ 857,009	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG45779				$ 630,807	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG46139				$ 221,141	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG50603				$ 904,243	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG53798	University of Southern California	AG53798		$ 6,403	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG54029	Massachusetts General Hospital	AG54029		$ 15,909	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG54199			$ 155,731	$ 575,898	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG54454				$ 8	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG55529			$ 9,434	$ 9,434	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG55549			$ 180,596	$ 733,351	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG56130	Sanford-Burnham Medical	AG56130		$ 442,954	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG56270	Columbia University	AG56270		$ 162,131	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG57195	Indiana University	AG57195		$ 686,907	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG57437	University of Southern California	AG57437		$ 1,418,921	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG58926	NYU Grossman School of Medicine	AG58926		$ 15,649	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG59416	CA Pacific Medical Center Research	AG59416		$ 347,160	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG59417	CA Pacific Medical Center Research	AG59417		$ 1,528	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG59798	Washington University in St. Louis	AG59798		$ 125,517	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG61100	Partners Health Care Research Management	AG61100		$ 178,357	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG61456			$ 45,195	$ 74,370	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG61848	University of Southern California	AG61848		$ 172,165	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62348	Boston University Medical Campus	AG62348	$ 30,599	$ 187,925	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62413			$ 700,975	$ 3,625,037	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62436			$ 33,663	$ 51,408	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62677				$ 4,480,965	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62689	University of California Berkeley	AG62689		$ 725,196	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62823	Arizona State University	AG62823		$ 1,003	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG62859				$ 643,646	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG63689	Brigham & Women's Hospital	AG63689		$ 55,274	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG63707				$ 127,937	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG63780				$ 652,061	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG63911	National Institute on Aging	AG63911		$ 2,868,994	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG63911			$ 6,839,039	$ 12,349,593	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG64029				$ 2,042	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65088	Minnesota HealthSolutions Corp	AG65088		$ 10,468	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65154			$ 1,706,209	$ 2,350,410	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65188	Duke University	AG65188		$ 159,089	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65204	American Federation for Aging	AG65204		$ 5,178	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65219				$ 142,916	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65248	University of Southern California	AG65248		$ 471,200	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65311	Beth Israel Deaconess Medical Center	AG65311		$ 17,817	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG65639				$ 17,004	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG66134	Columbia University	AG66134		$ 49,764	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG66395				$ 788,289	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG66429				$ 92,572	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG66768	Beth Israel Deaconess Medical Center	AG66768		$ 8,455	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG67418	University of California Berkeley	AG67418		$ 687,091	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG67631	Indiana University	AG67631		$ 4,592	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG67763			$ 47,704	$ 667,736	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68007				$ 550,891	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68034	North Dakota State University	AG68034		$ 177,814	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68048				$ 321,669	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68054	University of Pittsburgh	AG68054		$ 183,449	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68076				$ 174,810	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68128	University of Florida	AG68128		$ 51,735	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68141	Beth Israel Deaconess Medical Center	AG68141		$ 33,656	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68182				$ 144,932	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68192				$ 483,224	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG68206				$ 929,913	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68368				$ 140,735	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG68581	St. Jude Children's Research Hospital	AG68581		$ 246,056	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69052			$ 35,085	$ 914,230	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69264	University of Virginia	AG69264		$ 4,591	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69453	Banner Alzheimer's Institute	AG69453		$ 308,924	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69690	Cedars Sinai Medical Center	AG69690		$ 49,201	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69701			$ 4,546,850	$ 6,641,446	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69767			$ 29,925	$ 257,536	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG69822	NYU Grossman School of Medicine	AG69822		$ 56,635	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG70113				$ 159,663	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71190				$ 747,336	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71226				$ 377,325	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71513	University of South Florida	AG71513		$ 27,333	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71513				$ 28,398	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71686				$ 433,664	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71744	Hebrew Rehabilitation Center	AG71744		$ 42,758	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71754	Washington University in St. Louis	AG71754		$ 1,914,793	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG71807	Wake Forest University Health Scienc	AG71807		$ 1,051	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG72122	University of Washington	AG72122		$ 17,908	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG72719				$ 511,237	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG72799	Yale University	AG72799		$ 72,900	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG72898				$ 162,716	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG72980	Banner Alzheimer's Institute	AG72980		$ 164,478	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73119	University of Connecticut	AG73119		$ 91,923	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73267	University of Pittsburgh	AG73267		$ 271,805	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73282				$ 317,083	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73434	Georgia Institute of Technology	AG73434		$ 49,275	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73482	University California San Francisco	AG73482		$ 69,311	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73525				$ 148,245	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG73726				$ 20,834	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG74127	Minnesota HealthSolutions Corp	AG74127		$ 33,983	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG74867	University of Florida	AG74867		$ 358	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG74867			$ 63,039	$ 354,775	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG74879			$ 2,705,605	$ 6,661,509	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG75227			$ 107,081	$ 324,692	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG75802			$ 1,076,017	$ 2,488,762	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76122				$ 706,990	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76163				$ 40,523	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76401				$ 162,302	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76469				$ 271,655	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76515			$ 26,564	$ 354,041	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76518	Johns Hopkins University	AG76518		$ 171,834	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76537			$ 97,994	$ 432,276	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76636				$ 554,327	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG76662				$ 134,776	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG77656			$ 35,822	$ 692,327	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG77677	University of Miami	AG77677		$ 195,797	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG77706			$ 458,202	$ 1,067,641	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG77771			$ 333,010	$ 610,784	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG78105	NYU Grossman School of Medicine	AG78105		$ 180,065	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG78179				$ 148,243	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG78457	University California San Francisco	AG78457		$ 252,610	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG78555			$ 12,405	$ 26,626	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG78615			$ 253,042	$ 554,920	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG79113			$ 96,736	$ 528,383	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG79859				$ 417,637	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG80469	Regents of the University of California at San Francisco	AG80469		$ 123,205	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG80556				$ 981,711	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG80598	Beth Israel Deaconess Medical Center	AG80598		$ 11,984	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG80842	Beth Israel Deaconess Medical Center	AG80842		$ 69,560	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81203			$ 92,787	$ 958,090	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81223				$ 844,014	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81293	University of Pittsburgh	AG81293		$ 14,075	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81460				$ 156,269	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
AGING RESEARCH	93.866	AG81469	University of Wisconsin-Madison	AG81469		$ 4,910	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81582	Columbia University Medical Center	AG81582		$ 81,464	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81584				$ 354,862	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG81955			$ 146,963	$ 1,234,399	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82350	University of Washington	AG82350		$ 715,786	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82578	Minnesota HealthSolutions Corp	AG82578		$ 53,240	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82681			$ 8,158	$ 435,656	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82704			$ 166,004	$ 492,213	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82708			$ 5,776	$ 352,280	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG82919				$ 118,153	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG83039	University of Texas Health at Houston	AG83039		$ 692,986	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG83186			$ 24,804	$ 408,081	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG83464	Wake Forest University Health Scienc	AG83464		$ 48,220	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG83928	Northwestern University	AG83928		$ 7,609	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG83981	North Dakota State University	AG83981		$ 145,357	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG84154	University of Missouri	AG84154		$ 25,286	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG84236			$ 845,282	$ 1,403,722	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG84379	Synaptic Health LLC	AG84379		$ 34,087	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG84437	Hennepin Healthcare Research Institute	AG84437		$ 14,510	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG84733			$ 51,973	$ 1,011,682	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85029	Regents of the University of California at San Francisco	AG85029		$ 427,106	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85307	University of Colorado	AG85307		$ 112,749	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85314				$ 130,158	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85705				$ 140,922	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85900	University of Minnesota	AG85900		$ 81,634	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG85984				$ 52,813	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG86085			$ 26,454	$ 536,841	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG86136				$ 414,677	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG87140				$ 337,278	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG87165				$ 527,188	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG87361			$ 111,646	$ 180,160	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG87387				$ 386,180	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG88019	University of Florida	AG88019		$ 7,756	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG88076			$ 252,266	$ 644,523	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG88403				$ 290,826	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG88554				$ 269,474	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG89150			$ 300,287	$ 765,752	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG89237	Dana-Farber Cancer Institute	AG89237		$ 24,187	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG89335	University of California Los Angeles	AG89335		$ 49,178	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG89380			$ 89,459	$ 898,126	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG90337	University of Virginia	AG90337		$ 22,868	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG90341				$ 71,780	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG90487	Ohio State University	AG90487		$ 27,172	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG90601				$ 336,802	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG90620				$ 113,710	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG92355	University of Wisconsin-Madison	AG92355		$ 18,954	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG93316				$ 48,936	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG93767				$ 545,954	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG93815				$ 74,747	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG94182				$ 25,190	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG95792				$ 32,881	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
AGING RESEARCH	93.866	AG98157	University of Texas Health at Houston	AG98157		$ 5,461	$ 99,399,925	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY11751	JAEB Center for Health Research, Inc.	EY11751		$ 217,735	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY14231	JAEB Center for Health Research, Inc.	EY14231		$ 264,464	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY23384	University of Minnesota	EY23384		$ 165,262	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY30030	JAEB Center for Health Research, Inc.	EY30030		$ 49,675	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY31301				$ 298,928	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY31758				$ 172,794	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY33293	Johns Hopkins University	EY33293		$ 49,695	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY35084	University of Southern California	EY35084		$ 184,530	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
VISION RESEARCH	93.867	EY35533			$ 58,730	$ 335,340	$ 1,738,423	RESEARCH AND DEVELOPMENT	472,270,751
MEDICAL LIBRARY ASSISTANCE	93.879	LM11934	University of Texas Health at Houston	LM11934		$ 52,756	$ 118,117	RESEARCH AND DEVELOPMENT	472,270,751
MEDICAL LIBRARY ASSISTANCE	93.879	LM13438	Arizona State University	LM13438		$ 31,835	$ 118,117	RESEARCH AND DEVELOPMENT	472,270,751
MEDICAL LIBRARY ASSISTANCE	93.879	LM13606	University of North Carolina at Chapel Hill	LM13606		$ 543	$ 118,117	RESEARCH AND DEVELOPMENT	472,270,751
MEDICAL LIBRARY ASSISTANCE	93.879	LM14534	Pennsylvania State University	LM14534		$ 6,319	$ 118,117	RESEARCH AND DEVELOPMENT	472,270,751

MAYO CLINIC
SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS
Fiscal Period 1/1/2025 - 12/31/2025

Federal Awarding Agency/Program Title	Federal Assistance Listing Number	Additional Award Indentification	Name of Pass-through entity	Identifying Number Assigned by Pass-through Entity	Total Amount Passed Through to Subrecipients	Federal Expenditures	Federal Program Total	Cluster Name	Cluster Total
MEDICAL LIBRARY ASSISTANCE	93.879	LM14760				$ 26,664	$ 118,117	RESEARCH AND DEVELOPMENT	472,270,751
NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	MDH10327	Minnesota Department of Health	MDH10327		$ 210,628	$ 210,628	N/A	
HIV CARE FORMULA GRANTS	93.917	267010				$ 250,448	$ 347,072	RESEARCH AND DEVELOPMENT	472,270,751
HIV CARE FORMULA GRANTS	93.917	GRK%212096				$ 96,624	$ 347,072	RESEARCH AND DEVELOPMENT	472,270,751
TUBERCULOSIS DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION	93.947	NU52PS910245				$ 1,282,456	$ 1,282,456	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	1AY2AX000065	SRI International	1AY2AX000065		$ 67,302	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75A50120C00096				$ 11,709	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75A50124C00001	PPD Investigator Services, LLC	75A50124C00001		$ 8,696	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75D30119C06088				$ 161,935	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75D30121C10297	Children's Hospital of Boston	75D30121C10297		$ 50,991	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75D30122C13330	Children's Hospital of Boston	75D30122C13330		$ 28,813	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75N91020F00030				$ 280	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75N91021P00840				$ 34,574	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75N92019D00031	Boston University	75N92019D00031		$ 18,824	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75N92024D00012	Boston University	75N92024D00012		$ 119,069	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	75Q80120D00005				$ 195,285	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	80JSC022F0146	University of Colorado	80JSC022F0146		$ 237,440	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	AMA #8	American Medical Association	AMA #8		$ 19,985	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	ARG00001	University of Colorado	ARG00001		$ 95,490	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	HHNS-268-2018-00010I	University of Mississippi Medical Center	HHNS-268-2018-00010I		$ 213,278	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	HHS-N-275-2018-00003I	Duke Clinical Research Institute	HHS-N-275-2018-00003I		$ 7,420	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	HHSP233201500128I	Carradora Health	HHSP233201500128I		$ 1,437	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	HL67310	RTI International	HL67310		$ 3,161	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	N00189-24-P-Z565				$ 107,454	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
CONTRACT	93.RD	PC35143	University of Iowa	PC35143		$ 41,575	$ 1,424,718	RESEARCH AND DEVELOPMENT	472,270,751
MILITARY HEALTH PROFESSIONS SCHOLARSHIPS	93.U01	Office of the Surgeon General				$ 100,134	$ 100,134	N/A	
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES					**$ 51,522,355**	**$ 434,901,288**			
TOTAL EXPENDITURES OF FEDERAL AWARDS					**$ 53,347,658**	**$ 489,943,435**			

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic
Schedule of Expenditures of Florida State Financial Assistance
Year Ended December 31, 2025

Sponsor/CSFA Description/Project Description	CSFA Number	Contract / Grant / Subaward Number	Expenditures	Pass-Through to Subrecipients
STATE OF FLORIDA				
Department of Elder Affairs				
Direct Awards				
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZ907	$ 27,388	$ -
Alzheimer Interventions, Memory Disorder Clinics, Brain Banks and Alzheimer Special Projects	65.002	XZH22	735,819	-
Subtotal Direct Awards and CSFA Number 65.002			763,207	-
Total Department of Elder Affairs			763,207	-
Department of Health				
Direct Awards				
James and Esther King Biomedical Research Program	64.041	22K01	388,325	-
James and Esther King Biomedical Research Program	64.041	23K09	206,535	-
James and Esther King Biomedical Research Program	64.041	24K01	259,134	-
Subtotal CSFA Number 64.041			853,994	-
Bankhead-Coley Cancer Research Program	64.078	22B08	89,798	-
Bankhead-Coley Cancer Research Program	64.078	24B01	97,513	-
Bankhead-Coley Cancer Research Program	64.078	MOG18	1,627,765	-
Bankhead-Coley Cancer Research Program	64.078	MOG22	13,880,920	-
Subtotal CSFA Number 64.078			15,695,996	-
Florida Consortium of National Cancer Institute Centers Program	64.128	MOG22	24,983,528	-
Subtotal CSFA Number 64.128			24,983,528	-
Endowed Chair for Cancer Research	64.130	25C01	25,459	-
Endowed Chair for Cancer Research	64.130	25C19	234,894	-
Endowed Chair for Cancer Research	64.130	25C21	279,210	-
Endowed Chair for Cancer Research	64.130	25C23	215,699	-
Endowed Chair for Cancer Research	64.130	25C41	16,790	-
Endowed Chair for Cancer Research	64.130	MOAAM	385,443	-
Endowed Chair for Cancer Research	64.130	MOAAU	906,381	-
Endowed Chair for Cancer Research	64.130	MOAAV	50,993	-
Endowed Chair for Cancer Research	64.130	MOG07	592,270	-
Subtotal CSFA Number 64.130			2,707,139	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	20A10	9,264	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	22A07	95,765	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	23A03	3,499	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	23A04	41,972	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A06	58,588	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A07	144,698	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A08	35,671	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A09	72,414	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A10	30,590	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	24A19	56,033	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	25A11	33,253	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	25A12	6,933	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	25A13	1,359	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	25A14	22,945	-
Ed and Ethel Moore Alzheimer's Disease Research Program	64.135	25A15	13,393	-
Subtotal CSFA Number 64.135			626,377	-
Subtotal Direct Awards			44,867,034	-
Total Department of Health			44,867,034	-
Total Expenditures of State Financial Assistance			$ 45,630,241	$ -

See accompanying notes to schedules of expenditures of federal awards and Florida state financial assistance.

Mayo Clinic

Notes to Schedules of Expenditures of Federal Awards and Florida State Financial Assistance

December 31, 2025

1. Significant Accounting Policies

The accompanying schedules of expenditures of federal awards and Florida state financial assistance (the Schedules) include the federal and Florida state grant activity of Mayo Clinic under programs of the federal and Florida state government for the year ended December 31, 2025. The information in the Schedules is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (the Uniform Guidance), and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Because the Schedules only present a selected portion of the operations of Mayo Clinic, they are not intended to, and do not, present the financial position, results of operations, or cash flows of Mayo Clinic.

Expenditures reported in the Schedules are reported on the cash basis of accounting, except for the Student Financial Assistance Cluster, which are reported on the accrual basis of accounting. Under the cash basis, expenditures are recognized when paid rather than when the obligation is incurred. Such expenditures are reported following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Negative amounts reported on the Schedules represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

2. 10% De Minimis Cost Rate

Indirect cost rates for Mayo Clinic were based on applicable U.S. Department of Health and Human Services (HHS) negotiated rates, the 10% de minimis indirect cost rate allowed by the Uniform Guidance, or sponsor-specific (capped) rates.

3. Section 202 Direct Loans and Federal Direct Loans

The Supportive Housing for the Elderly, Section 202 Direct Loan (Assistance Listing No. 14.157) is considered a federal award until the outstanding balance is paid in full. At December 31, 2025, Bloomer Lakeview, Inc.’s outstanding balance is $30,147.

During the year, Mayo Clinic expended $16,605,252 in Federal Direct Student Loans (Assistance Listing No. 84.268), which includes Direct Stafford Loan and Parent Loan for Undergraduate Students from the federal government. The federal government is responsible for billings and collections of the loans. Mayo Clinic assists the federal government by processing the applications

Uniform Guidance Reports and Schedule

Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

Shape the future
with confidence

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Board of Trustees, Chief Executive Officer and President,
Chief Financial Officer, and Chief Administrative Officer
Mayo Clinic

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the financial statements of Mayo Clinic ("the Clinic"), which comprise the consolidated statement of financial position as of December 31, 2025, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes (collectively referred to as the "financial statements"), and have issued our report thereon dated March 2, 2026.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Clinic's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control. Accordingly, we do not express an opinion on the effectiveness of the Clinic's internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

A member firm of Ernst & Young Global Limited

Shape the future
with confidence

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Clinic's financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst & Young LLP

March 2, 2026

A member firm of Ernst & Young Global Limited

Ernst & Young LLP
Suite 500
700 Nicollet Mall
Minneapolis, MN 55402

Tel: +1 612 343 1000
ey.com

Shape the future
with confidence

Report of Independent Auditors on Compliance for the Major Federal Program and State Financial Assistance Project and Report on Internal Control Over Compliance Required by the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*

The Board of Trustees, Chief Executive Officer and President,
Chief Financial Officer, and Chief Administrative Officer
Mayo Clinic

Report of Independent Auditors on Compliance for the Major Federal Program and State Financial Assistance Project

Opinion on the Major Federal Program and State Financial Assistance Project

We have audited Mayo Clinic's ("the Clinic") compliance with the types of compliance requirements identified as subject to audit in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* and the Florida Department of Financial Services' *State Projects Compliance Supplement* that could have a direct and material effect on the Clinic's major federal program and state financial assistance project for the year ended December 31, 2025. The Clinic's major federal program and state financial assistance project are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Clinic complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program and state financial assistance project for the year ended December 31, 2025.

Basis for Opinion on the Major Federal Program and State Financial Assistance Project

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*); the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance); and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Our responsibilities under those standards, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

A member firm of Ernst & Young Global Limited

We are required to be independent of the Clinic and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on compliance for the major federal program and state financial assistance project. Our audit does not provide a legal determination of the Clinic's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Clinic's federal programs and state financial assistance projects.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Clinic's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida* will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Clinic's compliance with the requirements of the major federal program and state financial assistance project as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, the Uniform Guidance, and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Clinic's compliance with the compliance

A member firm of Ernst & Young Global Limited

requirements referred to above and performing such other procedures as we considered necessary in the circumstances.

- Obtain an understanding of the Clinic's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*, but not for the purpose of expressing an opinion on the effectiveness of the Clinic's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A *deficiency in internal control over compliance* exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct noncompliance with a type of compliance requirement of a federal program or state financial assistance project on a timely basis. A *material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program or state financial assistance project will not be prevented, or detected and corrected on a timely basis. A *significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program or state financial assistance project that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations during our audit, we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

A member firm of Ernst & Young Global Limited

Shape the future
with confidence

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance and Chapter 10.650, *Rules of the Auditor General of the State of Florida*. Accordingly, this report is not suitable for any other purpose.

Ernst & Young LLP

June 18, 2026

A member firm of Ernst & Young Global Limited

Mayo Clinic

Schedule of Findings and Questioned Costs

For the Year Ended December 31, 2025

Section I – Summary of Auditor's Results

Financial Statements

Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP:	Unmodified	
Internal control over financial reporting:		
Material weakness(es) identified?	____ **Yes**	X **No**
Significant deficiency(ies) identified?	____ **Yes**	X **None Reported**
Noncompliance material to financial statements noted?	____ **Yes**	X **No**

Federal Awards

Internal control over major federal program: Material weakness(es) identified?	____ **Yes**	X **No**
Significant deficiency(ies) identified?	____ **Yes**	X **None Reported**
Type of auditor's report issued on compliance for major federal program:	Unmodified	
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	____ **Yes**	X **No**

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

For the Year Ended December 31, 2025

Section I – Summary of Auditor's Results (continued)

Identification of major federal program:

Assistance Listing Numbers	Name of Federal Program or Cluster
Multiple	Research and Development Cluster

Dollar threshold used to distinguish between Type A and Type B programs:	$3,000,000		
Auditee qualified as low-risk auditee?	**Yes**	X **No**	

Florida State Financial Assistance Projects

Internal control over major state financial assistance project:			
Material weakness(es) identified?	**Yes**	X **No**	
Significant deficiency(ies) identified?	**Yes**	X **None Reported**	
Type of auditor's report issued on compliance for major state financial assistance project:	Unmodified		
Any audit findings disclosed that are required to be reported in accordance with Chapter 10.650, *Rules of the Auditor General of the State of Florida*?	**Yes**	X **No**	

Section I – Summary of Auditor's Results (continued)

Identification of major state financial assistance project:

State CSFA Number	Name of State Financial Assistance Project
64.128	Florida Consortium of National Cancer Institute Centers Program
Dollar threshold used to distinguish between Type A and Type B state financial assistance projects:	$1,368,907

Mayo Clinic

Schedule of Findings and Questioned Costs (continued)

For the Year Ended December 31, 2025

Section II – Financial Statement Findings

None identified.

Section III – Federal Award and State Financial Assistance Project Findings and Questioned Costs

None identified.

EY | Building a better working world

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow.

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multidisciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2026 Ernst & Young LLP.
All Rights Reserved.

ey.com

MAYO CLINIC

Summary Schedule of Prior Audit Findings – For the Years Ended December 31, 2024 and 2023

Finding 2024-001 – Preparation of the Schedule of Expenditures of Florida State Financial Assistance

Identification of the state of Florida projects:
State of Florida Agency: Department of Health
SFA Nos.: 64.041 (James and Esther King Biomedical Research Program), 64.078 (BankheadColey Cancer Research Program), 64.128 (Florida Consortium of National Cancer Institute Centers Program), 64.130 (Endowed Chair for Cancer Research), and 64.135 (Ed and Ethel Moore Alzheimer's Disease Research Program)

Summary of Prior Audit Finding

Condition:
Expenditures were misclassified to the incorrect CSFA Nos. for five of six state of Florida projects reported in the Schedule.

Recommendation:
Management should implement more robust internal controls to ensure all state of Florida expenditures are appropriately classified and reported in the Schedule.

Status

Completed. Management has reviewed controls over data capture for the creation of the schedule and has strengthened controls to ensure accurate preparation.

Finding 2024-002 – Cash Management

Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services, U.S. Department of Defense and National Science Foundation.
Federal Cluster: Research and Development (R&D)
Assistance Listing Nos.: 12.300, 12.420, 12.RDC, 47.070, 93.350, 93.840, 93.121, 93.172, 93.173, 93.226, 93.242, 93.273, 93.279, 93.286, 93.353, 93.361, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, 93.866, 93.867, and 93.RD
Award Numbers: Various
Award Periods: Various

Summary of Prior Audit Finding

Condition:
The Clinic did not perform its monthly review control timely related to payments made to subrecipients.

Recommendation:
Management should ensure timely review of subrecipient payments based on the established internal controls and policies.

Status
Completed. In 2024, management finalized revisions to the reports used to monitor subrecipient payments. Corrective actions have been implemented as of March 31, 2025 and the reports and monitoring process are functioning as intended and all reviews are current.

Finding 2024-003 – Subrecipient Monitoring

Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Federal Cluster: Research and Development (R&D)
Assistance Listing Nos.: 12.300, 12,420, 93.279, 93.286, 93.393, 93.394, 93.395, 93.396, 93.397, 93.837, 93.838, 93.839, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866
Award Numbers: Various
Award Periods: Various

Summary of Prior Audit Finding
Condition:
Required subrecipient monitoring activities were not consistently performed related to annual subrecipient risk assessments. In addition, subaward monitoring checklists were not consistently completed or retained to evidence the results of the monitoring performed over subrecipients by principal investigators during the fiscal year.

Recommendation:
The Clinic should ensure that the annual subrecipient risk assessments and subrecipient monitoring checklists are completed timely and documentation is retained to support the operating effectiveness of established internal controls

Status
Completed. In 2024, management finalized revisions to the reports used to complete subrecipient risk assessments. Corrective actions have been implemented as of January 1, 2025, and the reports and process are functioning as intended and assessments are current.
Control processes for subrecipients monitoring checklists have been modified to ensure complete and timely documentation is retained.

Finding 2024-004 – Activities Allowed or Unallowed and Allowable Costs
Identification of the state of Florida project:
State of Florida Agency: Department of Health
CSFA No.: 64.128
Award Number: MOG22
Award Period: 07/01/2023−06/30/2025

Summary of Prior Audit Finding
Condition:
Documentation of review and approval of allowability of internal service charges by the Principal Investigator (PI) or appropriate individual with knowledge of the grant was not consistently maintained at a transactional level during the fiscal year.

Recommendation:
The Clinic should ensure that internal service transaction requests are reviewed timely, and documentation is retained to support the operating effectiveness of established internal controls.

Status
Completed. Corrective actions were implemented as of June 30, 2025 whereby management implemented revisions to the control processes retrospectively to January 1, 2025, to provide evidence of review and conclusions reached over the allowability of internal service charges on State of Florida awards. Communication has occurred to ensure awareness and understanding of control process documentation.

Finding 2023-001 – N2 Disbursements to or on Behalf of Students
Identification of the federal program:
Federal Agency: United States Department of Education
Federal Cluster: Student Financial Assistance
Assistance Listing No.: 84.268, Federal Direct Student Loans (Direct Loans)
Award Periods: July 1, 2022 through June 30, 2023; July 1, 2023 through June 30, 2024

Summary of Prior Audit Finding
Condition:
When Direct Loans are being credited to a student's account, an institution must notify the student, or parent, in writing of (1) the date and amount of the disbursement; (2) the student's right, or parent's right, to cancel all or a portion of that loan or loan disbursement and have the loan proceeds returned to the holder of that loan; and (3) the procedure and time by which the student or parent must notify the institution that he or she wishes to cancel the loan. In order to identify these students, Mayo Clinic ("the Clinic") utilizes a disbursement report that is run from a script housed in SAP Business Objects. Information technology general controls (ITGCs) over the SAP Business Objects disbursement report was not tested by the Clinic during 2023 to ensure the accuracy and completeness of the disbursement report.

Recommendation:
The Clinic should implement internal controls to ensure SAP Business Objects ITGCs are tested or implement compensating controls to ensure the disbursement report is accurate and complete.

Status
Completed. Annual tests of access to Business Objects and properly authorized changes made to the logic within Business Objects specific to the disbursement report used by management will be conducted. Testing will be performed initially by Mayo Clinic's internal audit team and in subsequent years by the Financial Aid Director and Director of Data Analytics.

Finding 2023-002 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles
Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Pass-Through Entities: Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, University of Chicago, University of Michigan, and Washington University
Federal Cluster: Research and Development (R&D) Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.865, and 93.866

Award Numbers: Various
Award Periods: Various

Summary of Prior Audit Finding

Condition:
Evidence of review of allowability of internal service charges at a transactional level by the Principal Investigator (PI) or appropriate individual with authority on the grant was not retained during the fiscal year.

Recommendation:
Beginning in fiscal year 2024, the PI monthly/quarterly review packet was redesigned to provide evidence of review and conclusions reached over internal service charges transaction detail. Management should ensure that the newly implemented control is operating as designed.

Status
Completed. Management implemented revisions to the monthly/quarterly review packet in January 2024 to ensure review of internal service charges and retention of review documentation. Management's expectations have been communicated to those responsible for the control process regarding timely reviews and retention of documentation.

Finding 2023-003 – Subrecipient Monitoring
Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Federal Cluster: Research and Development (R&D) Assistance Listing Nos.: 12.RDC, 12.300, 93.393, 93.396, 93.847, 93.853, 93.859
Award Numbers: Various
Award Periods: Various

Summary of Prior Audit Finding
Condition:
Subaward monitoring checklists were not consistently completed or retained to evidence the results of the monitoring performed over subrecipients by principal investigators during the fiscal year.

Recommendation:
The Clinic should ensure that the subrecipient monitoring checklist is completed timely and documentation is retained to support the operating effectiveness of established internal controls.

Status
Completed. Monthly/quarterly reviews, including completion of subaward monitoring checklists, resumed in January 2024. Management's expectations have been communicated to those responsible for the control process regarding timely checklist completion and retention of documentation.

Finding 2023-004 – Activities Allowed or Unallowed and Allowable Costs/Cost Principles
Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Pass-Through Entities: Boston University, Georgia Institute of Technology, Massachusetts General Hospital, NYU Grossman School of Medicine, Stanford University, The University of Texas, University of Buffalo, University of Chicago, and Washington University
Federal Cluster: Research and Development (R&D)

Assistance Listing Nos.: 12.300, 12.420, 93.233, 93.273, 93.279, 93.310, 93.350, 93.393, 93.395, 93.396, 93.397, 93.837, 93.838, 93.846, 93.847, 93.853, 93.855, 93.859, 93.865, and 93.866
Award Numbers: Various
Award Periods: Various

Identification of the state projects:
State Grantor: State of Florida Department of Health (DOH) Catalog of State Financial Assistance (CSFA) No.: 64.130, Endowed Chair for Cancer Research Award Number: MOG07 Award Period: July 1, 2014 – until expended State Grantor: State of Florida Department of Health (DOH) Catalog of State Financial Assistance (CSFA) No.: 64.135, Ed and Ethel Moore Alzheimer's Disease Research Program Award Numbers: 20A10, 22A04, 22A05, 22A06, 22A07, 22A08, 22A09, 22K01, 23A03, 23A04, and 23K09 Award Periods: Various

Summary of Prior Audit Finding
Condition:
Internal controls over effort reporting were not operating effectively from April 1, 2023 through May 31, 2023 and, therefore, could not be relied upon.
Internal controls over salary cap were not operating effectively from April 1, 2023 through December 31, 2023 and therefore, could not be relied upon.

Recommendation:
Management should ensure effort report certifications and approvals are performed monthly. In addition, management should review the design of the payroll salary cap application to ensure it is appropriately calculating salary expenses during the effort certification process.

Status
Completed. Management has made improvements to the salary cap application to ensure salaries are being correctly charged. The salary cap application is working effectively as of January 1, 2024.

Finding 2023-005 – Procurement, Suspension and Debarment
Identification of the federal program:
Federal Agencies: U.S. Department of Health and Human Services and U.S. Department of Defense
Federal Cluster: Research and Development (R&D) Pass-Through Entity: The University of Texas Health (93.853, NS119834)
Assistance Listing Nos.: 12.420, 93.310, 93.353, 93.393, and 93.853
Award Numbers: W81XWH-15-1-0292 (12.420), OD23121 (93.310), CA246568 (93.353), CA259201 (93.393), NS119834 (93.853), NS122096 (93.853)
Award Periods: Various

Summary of Prior Audit Finding
Condition:
Internal Control
For five (56%) of nine procurement transactions tested for operating effectiveness of internal controls, the procurement justification form used by the Clinic to document the history of the procurement and compliance with Uniform Guidance CFR 200.303, was not completed until after the purchase order was created and/or invoice received from the vendor. In addition, for these same five procurement transactions, the Clinic did not timely document its suspension and debarment check at the time of procurement as required by its procurement justification form.
In addition, for four (44%) of nine procurement transactions tested for operating effectiveness of internal controls (two of which relate to the five cited above), the procurement justification form used by the

Clinic to document the procurement transaction's compliance with policies, procedures and the Uniform Guidance was outdated.
Furthermore, the monthly review of completed procurement justification forms related to procurements > $25,000 to ensure they are documented in accordance with the Clinic's procurement, suspension and debarment policies and procedures was not operating effectively.
Compliance
For one (9%) of 11 procurement transactions tested for compliance, the procurement was an addon purchase related to a larger procurement of the same product under a prior purchase order. The prior procurement was above the simplified acquisition threshold and the Clinic's competitive bid threshold. The Clinic did not complete a procurement justification form for the add-on purchase (which was a small purchase), and the original procurement did not have adequate support to evidence that it had been competitively bid. As such, adequate documentation did not exist for the procurement in accordance with Uniform Guidance Section 230.320(a)(2)(i) and(b).
In addition, for five procurement transactions, the Clinic did not follow its suspension and debarment procedures as required by its procurement justification form.

Recommendation:
The Clinic should ensure that all R&D awards that require procurement of goods and services follow established policies, procedures, and internal controls to comply with the Uniform Guidance procurement standards and that the procurement justification form is reviewed prior to entering into the purchase transaction. The Clinic should ensure that independent checks for suspension and debarment should be timely completed at the time of procurement in accordance with the Clinic documented policies, procedures, and internal controls.

Status
Completed. Management conducted an education and training session for procurement teams in June 2024 to reinforce procurement requirements and documentation standards. Management implemented an independent sanction and debarment check for suppliers as part of existing quarterly audits over Supplier AP vendor master tables and related changes to those tables.